1
|
Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA, Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W, Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K, Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer 2024; 5:517-531. [PMID: 38216766 DOI: 10.1038/s43018-023-00709-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Accepted: 12/13/2023] [Indexed: 01/14/2024]
Abstract
We previously showed that chimeric antigen receptor (CAR) T-cell therapy targeting epidermal growth factor receptor variant III (EGFRvIII) produces upregulation of programmed death-ligand 1 (PD-L1) in the tumor microenvironment (TME). Here we conducted a phase 1 trial (NCT03726515) of CAR T-EGFRvIII cells administered concomitantly with the anti-PD1 (aPD1) monoclonal antibody pembrolizumab in patients with newly diagnosed, EGFRvIII+ glioblastoma (GBM) (n = 7). The primary outcome was safety, and no dose-limiting toxicity was observed. Secondary outcomes included median progression-free survival (5.2 months; 90% confidence interval (CI), 2.9-6.0 months) and median overall survival (11.8 months; 90% CI, 9.2-14.2 months). In exploratory analyses, comparison of the TME in tumors harvested before versus after CAR + aPD1 administration demonstrated substantial evolution of the infiltrating myeloid and T cells, with more exhausted, regulatory, and interferon (IFN)-stimulated T cells at relapse. Our study suggests that the combination of CAR T cells and PD-1 inhibition in GBM is safe and biologically active but, given the lack of efficacy, also indicates a need to consider alternative strategies.
Collapse
Affiliation(s)
- Stephen J Bagley
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
| | - Zev A Binder
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- GBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Lamia Lamrani
- Clinical Immunology Laboratory, Institut Curie, Paris, France
- INSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France
- Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
| | - Eliana Marinari
- Agora Cancer Research Center, Lausanne, Switzerland
- Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Léman, Lausanne and Geneva, Geneva, Switzerland
- Department of Oncology, University Hospital of Geneva, Geneva, Switzerland
| | - Arati S Desai
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - MacLean P Nasrallah
- GBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Eileen Maloney
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Steven Brem
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- GBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Robert A Lustig
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Goldie Kurtz
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Michelle Alonso-Basanta
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Pierre-Emmanuel Bonté
- INSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France
| | - Christel Goudot
- INSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France
| | - Wilfrid Richer
- INSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France
- Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France
| | - Eliane Piaggio
- INSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France
| | - Shawn Kothari
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
| | - Lea Guyonnet
- Cytometry Platform, CurieCoreTech, Institut Curie, Paris, France
| | - Coralie L Guerin
- Cytometry Platform, CurieCoreTech, Institut Curie, Paris, France
| | - Joshua J Waterfall
- Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France
- INSERM U830, PSL University, Institut Curie Research Cente, Paris, France
| | - Suyash Mohan
- Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Wei-Ting Hwang
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Oliver Y Tang
- GBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Warren Alpert Medical School of Brown University, Providence, RI, USA
| | - Meghan Logun
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- GBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Meghna Bhattacharyya
- GBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Cooper Medical School of Rowan University, Camden, NJ, USA
| | - Kelly Markowitz
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Devora Delman
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Amy Marshall
- Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - E John Wherry
- Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Institute for Immunology and Immune Health, Cambridge, MA, USA
| | - Sebastian Amigorena
- INSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France
| | - Gregory L Beatty
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- GBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | | | - Elizabeth Hexner
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Denis Migliorini
- Agora Cancer Research Center, Lausanne, Switzerland
- Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Léman, Lausanne and Geneva, Geneva, Switzerland
- Department of Oncology, University Hospital of Geneva, Geneva, Switzerland
| | - Cecile Alanio
- Clinical Immunology Laboratory, Institut Curie, Paris, France.
- INSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France.
- Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
| | - Donald M O'Rourke
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- GBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
2
|
Thiolat A, Pilon C, Caudana P, Moatti A, To NH, Sedlik C, Leclerc M, Maury S, Piaggio E, Cohen JL. Treg-targeted IL-2/anti-IL-2 complex controls graft- versus-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation. Haematologica 2024; 109:129-142. [PMID: 37706355 PMCID: PMC10772500 DOI: 10.3324/haematol.2022.282653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 09/07/2023] [Indexed: 09/15/2023] Open
Abstract
Modulating an immune response in opposite directions represents the holy grail in allogeneic hematopoietic stem cell transplantation (allo-HSCT) to avoid insufficient reactivity of donor T cells and hematologic malignancy relapse while controlling the potential development of graft-versus-host disease (GVHD), in which donor T cells attack the recipient's tissues. IL-2/anti-IL-2 complexes (IL-2Cx) represent a therapeutic option to selectively accentuate or dampen the immune response. In dedicated experimental models of allo-HSCT, including also human cells injected in immunodeficient NSG mice, we evaluated side-by-side the therapeutic effect of two IL-2Cx designed either to boost regulatory T cells (Treg) or alternatively to activate effector T cells (Teff), on GVHD occurrence and tumor relapse. We also evaluated the effect of the complexes on the phenotype and function of immune cells in vivo. Unexpectedly, both pro-Treg and pro-Teff IL-2Cx prevented GVHD development. They both induced Treg expansion and reduced CD8+ T-cell numbers, compared to untreated mice. However, only mice treated with the pro-Treg IL-2Cx, showed a dramatic reduction of exhausted CD8+ T cells, consistent with a potent anti-tumor effect. When evaluated on human cells, pro-Treg IL-2Cx also preferentially induced Treg expansion in vitro and in vivo, while allowing the development of a potent anti-tumor effect in NSG mice. Our results demonstrate the clinical relevance of using a pro-Treg, but not a pro-Teff IL2Cx to modulate alloreactivity after HSCT, while promoting a graft-versus-leukemia effect.
Collapse
Affiliation(s)
- Allan Thiolat
- Univ Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil
| | - Caroline Pilon
- Univ Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France; AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Centre d'Investigation Clinique Biothérapie, Fédération hospitalo-Universitaire TRUE, F-94010 Créteil
| | - Pamela Caudana
- INSERM U932, PSL Research University, Institute Curie Research Center, Paris, France; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris
| | - Audrey Moatti
- Univ Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil
| | - Nhu Hanh To
- Univ Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil
| | - Christine Sedlik
- INSERM U932, PSL Research University, Institute Curie Research Center, Paris, France; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris
| | - Mathieu Leclerc
- Univ Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France; AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Service d'Hématologie Clinique, F-94010 Créteil
| | - Sébastien Maury
- Univ Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France; AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Centre d'Investigation Clinique Biothérapie, Fédération hospitalo-Universitaire TRUE, F-94010 Créteil, France; AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Service d'Hématologie Clinique, F-94010 Créteil
| | - Eliane Piaggio
- INSERM U932, PSL Research University, Institute Curie Research Center, Paris, France; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris
| | - José L Cohen
- Univ Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France; AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Centre d'Investigation Clinique Biothérapie, Fédération hospitalo-Universitaire TRUE, F-94010 Créteil.
| |
Collapse
|
3
|
Gerber-Ferder Y, Cosgrove J, Duperray-Susini A, Missolo-Koussou Y, Dubois M, Stepaniuk K, Pereira-Abrantes M, Sedlik C, Lameiras S, Baulande S, Bendriss-Vermare N, Guermonprez P, Passaro D, Perié L, Piaggio E, Helft J. Breast cancer remotely imposes a myeloid bias on haematopoietic stem cells by reprogramming the bone marrow niche. Nat Cell Biol 2023; 25:1736-1745. [PMID: 38036749 DOI: 10.1038/s41556-023-01291-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 10/17/2023] [Indexed: 12/02/2023]
Abstract
Myeloid cell infiltration of solid tumours generally associates with poor patient prognosis and disease severity1-13. Therefore, understanding the regulation of myeloid cell differentiation during cancer is crucial to counteract their pro-tumourigenic role. Bone marrow (BM) haematopoiesis is a tightly regulated process for the production of all immune cells in accordance to tissue needs14. Myeloid cells differentiate during haematopoiesis from multipotent haematopoietic stem and progenitor cells (HSPCs)15-17. HSPCs can sense inflammatory signals from the periphery during infections18-21 or inflammatory disorders22-27. In these settings, HSPC expansion is associated with increased myeloid differentiation28,29. During carcinogenesis, the elevation of haematopoietic growth factors supports the expansion and differentiation of committed myeloid progenitors5,30. However, it is unclear whether cancer-related inflammation also triggers demand-adapted haematopoiesis at the level of multipotent HSPCs. In the BM, HSPCs reside within the haematopoietic niche which delivers HSC maintenance and differentiation cues31-35. Mesenchymal stem cells (MSCs) are a major cellular component of the BM niche and contribute to HSC homeostasis36-41. Modifications of MSCs in systemic disorders have been associated with HSC differentiation towards myeloid cells22,42. It is unknown if MSCs are regulated in the context of solid tumours and if their myeloid supportive activity is impacted by cancer-induced systemic changes. Here, using unbiased transcriptomic analysis and in situ imaging of HSCs and the BM niche during breast cancer, we show that both HSCs and MSCs are transcriptionally and spatially modified. We demonstrate that breast tumour can distantly remodel the cellular cross-talks in the BM niche leading to increased myelopoiesis.
Collapse
Affiliation(s)
- Yohan Gerber-Ferder
- Institut Curie, Immunity and Cancer, PSL University, INSERM U932, Paris, France
- Université Paris Cité, INSERM U932, Paris, France
| | - Jason Cosgrove
- PSL University, Institut Curie Research Center, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, Paris, France
| | - Aleria Duperray-Susini
- Institut Cochin, Leukemia and Niche Dynamics Laboratory, Université Paris Cité, INSERM, CNRS, Paris, France
| | | | - Marine Dubois
- Institut Curie, Immunity and Cancer, PSL University, INSERM U932, Paris, France
| | - Kateryna Stepaniuk
- Institut Cochin, Phagocytes and Cancer Immunology Laboratory, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France
| | - Manuela Pereira-Abrantes
- Cancer Research Center of Lyon, Centre Léon Bérard, Université Claude Bernard Lyon 1, UMR INSERM 1052 CNRS 5286, Lyon, France
| | - Christine Sedlik
- Institut Curie, Immunity and Cancer, PSL University, INSERM U932, Paris, France
| | - Sonia Lameiras
- Institut Curie, ICGex Next-Generation Sequencing Platform, PSL University, Paris, France
- Institut Curie, Single Cell Initiative, PSL University, Paris, France
| | - Sylvain Baulande
- Institut Curie, ICGex Next-Generation Sequencing Platform, PSL University, Paris, France
- Institut Curie, Single Cell Initiative, PSL University, Paris, France
| | - Nathalie Bendriss-Vermare
- Cancer Research Center of Lyon, Centre Léon Bérard, Université Claude Bernard Lyon 1, UMR INSERM 1052 CNRS 5286, Lyon, France
| | - Pierre Guermonprez
- Institut Pasteur, Dendritic Cells and Adaptive Immunity Unit, Université Paris Cité, Paris, France
- Institut Pasteur, Université Paris Cité, CNRS UMR3738, Paris, France
| | - Diana Passaro
- Institut Cochin, Leukemia and Niche Dynamics Laboratory, Université Paris Cité, INSERM, CNRS, Paris, France
| | - Leïla Perié
- PSL University, Institut Curie Research Center, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, Paris, France
| | - Eliane Piaggio
- Institut Curie, Immunity and Cancer, PSL University, INSERM U932, Paris, France
| | - Julie Helft
- Institut Cochin, Phagocytes and Cancer Immunology Laboratory, Université Paris Cité, INSERM U1016, CNRS UMR8104, Paris, France.
| |
Collapse
|
4
|
Bonté PE, Metoikidou C, Heurtebise-Chretien S, Arribas YA, Sutra Del Galy A, Ye M, Niborski LL, Zueva E, Piaggio E, Seguin-Givelet A, Girard N, Alanio C, Burbage M, Goudot C, Amigorena S. Selective control of transposable element expression during T cell exhaustion and anti-PD-1 treatment. Sci Immunol 2023; 8:eadf8838. [PMID: 37889984 DOI: 10.1126/sciimmunol.adf8838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 09/01/2023] [Indexed: 10/29/2023]
Abstract
In chronic infections and cancer, T cells are exposed to prolonged antigen stimulation, resulting in loss of function (or exhaustion) and impairment of effective immunological protection. Exhausted T cells are heterogeneous and include early progenitors (Tpex) and terminally exhausted cells (Tex). Here, we used bulk and single-cell transcriptomics to analyze expression of transposable elements (TEs) in subpopulations of mouse and human CD8+ tumor-infiltrating T lymphocytes (TILs). We show that in mice, members of the virus-like murine VL30 TE family (mostly intact, evolutionary young ERV1s) are strongly repressed in terminally exhausted CD8+ T cells in both tumor and viral models of exhaustion. Tpex expression of these VL30s, which are mainly intergenic and transcribed independently of their closest gene neighbors, was driven by Fli1, a transcription factor involved in progression from Tpex to Tex. Immune checkpoint blockade (ICB) in both mice and patients with cancer increased TE expression (including VL30 in mice), demonstrating that TEs may be applicable as ICB response biomarkers. We conclude that expression of TEs is tightly regulated in TILs during establishment of exhaustion and reprogramming by ICB. Analyses of TE expression on single cells and bulk populations open opportunities for understanding immune cell identity and heterogeneity, as well as for defining cellular gene expression signatures and disease biomarkers.
Collapse
Affiliation(s)
- Pierre-Emmanuel Bonté
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| | - Christina Metoikidou
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| | | | - Yago A Arribas
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| | | | - Mengliang Ye
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| | | | - Elina Zueva
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| | - Eliane Piaggio
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| | | | - Nicolas Girard
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
- Institut Curie, Institut du Thorax Curie Montsouris, Paris 75005, France
- Paris Saclay, UVSQ, UFR Simmone Veil, Versailles 78000, France
| | - Cécile Alanio
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
- Laboratoire d'immunologie clinique, Institut Curie, Paris 75005, France
- Parker Institute of Cancer Immunotherapy, San Francisco, CA, USA
| | - Marianne Burbage
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| | - Christel Goudot
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| | - Sebastian Amigorena
- Institut Curie, PSL University, Inserm U932, Immunity and Cancer, Paris 75005, France
| |
Collapse
|
5
|
Lobón-Iglesias MJ, Andrianteranagna M, Han ZY, Chauvin C, Masliah-Planchon J, Manriquez V, Tauziede-Espariat A, Turczynski S, Bouarich-Bourimi R, Frah M, Dufour C, Blauwblomme T, Cardoen L, Pierron G, Maillot L, Guillemot D, Reynaud S, Bourneix C, Pouponnot C, Surdez D, Bohec M, Baulande S, Delattre O, Piaggio E, Ayrault O, Waterfall JJ, Servant N, Beccaria K, Dangouloff-Ros V, Bourdeaut F. Imaging and multi-omics datasets converge to define different neural progenitor origins for ATRT-SHH subgroups. Nat Commun 2023; 14:6669. [PMID: 37863903 PMCID: PMC10589300 DOI: 10.1038/s41467-023-42371-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 10/09/2023] [Indexed: 10/22/2023] Open
Abstract
Atypical teratoid rhabdoid tumors (ATRT) are divided into MYC, TYR and SHH subgroups, suggesting diverse lineages of origin. Here, we investigate the imaging of human ATRT at diagnosis and the precise anatomic origin of brain tumors in the Rosa26-CreERT2::Smarcb1flox/flox model. This cross-species analysis points to an extra-cerebral origin for MYC tumors. Additionally, we clearly distinguish SHH ATRT emerging from the cerebellar anterior lobe (CAL) from those emerging from the basal ganglia (BG) and intra-ventricular (IV) regions. Molecular characteristics point to the midbrain-hindbrain boundary as the origin of CAL SHH ATRT, and to the ganglionic eminence as the origin of BG/IV SHH ATRT. Single-cell RNA sequencing on SHH ATRT supports these hypotheses. Trajectory analyses suggest that SMARCB1 loss induces a de-differentiation process mediated by repressors of the neuronal program such as REST, ID and the NOTCH pathway.
Collapse
Affiliation(s)
- María-Jesús Lobón-Iglesias
- INSERM U830, Laboratory of Translational Research In Pediatric Oncology, PSL Research University, SIREDO Oncology center, Institut Curie Research Center, Paris, France
| | - Mamy Andrianteranagna
- INSERM U830, Laboratory of Translational Research In Pediatric Oncology, PSL Research University, SIREDO Oncology center, Institut Curie Research Center, Paris, France
- INSERM U900, Bioinformatics, Biostatistics, Epidemiology and Computational Systems Unit, Institut Curie, Mines Paris Tech, PSL Research University, Institut Curie Research Center, Paris, France
| | - Zhi-Yan Han
- INSERM U830, Laboratory of Translational Research In Pediatric Oncology, PSL Research University, SIREDO Oncology center, Institut Curie Research Center, Paris, France
| | - Céline Chauvin
- INSERM U830, Laboratory of Translational Research In Pediatric Oncology, PSL Research University, SIREDO Oncology center, Institut Curie Research Center, Paris, France
| | - Julien Masliah-Planchon
- Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France
| | - Valeria Manriquez
- INSERM U932, Immunity and Cancer, PSL Research University, Institut Curie Research Center, Paris, France
| | - Arnault Tauziede-Espariat
- Department of Neuropathology, GHU Paris-Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France
- Paris Psychiatry and Neurosciences Institute (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France
| | - Sandrina Turczynski
- INSERM U830, Laboratory of Translational Research In Pediatric Oncology, PSL Research University, SIREDO Oncology center, Institut Curie Research Center, Paris, France
| | - Rachida Bouarich-Bourimi
- INSERM U830, Laboratory of Translational Research In Pediatric Oncology, PSL Research University, SIREDO Oncology center, Institut Curie Research Center, Paris, France
| | - Magali Frah
- INSERM U830, Laboratory of Translational Research In Pediatric Oncology, PSL Research University, SIREDO Oncology center, Institut Curie Research Center, Paris, France
| | - Christelle Dufour
- Department of Children and Adolescents Oncology, Gustave Roussy, Paris Saclay University, Villejuif, France
| | - Thomas Blauwblomme
- Department of Pediatric Neurosurgery-AP-HP, Necker Sick Kids Hospital, Université de Paris, Paris, France
| | | | - Gaelle Pierron
- Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France
| | - Laetitia Maillot
- Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France
| | - Delphine Guillemot
- Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France
| | - Stéphanie Reynaud
- Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France
| | - Christine Bourneix
- Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France
| | - Célio Pouponnot
- CNRS UMR 3347, INSERM U1021, Institut Curie, PSL Research University, Université Paris-Saclay, Orsay, France
| | - Didier Surdez
- INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Center, Institut Curie Research Center, Paris, France
- Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Zurich, Switzerland
| | - Mylene Bohec
- Institut Curie, PSL University, Single Cell Initiative, ICGex Next-Generation Sequencing Platform, PSL University, 75005, Paris, France
| | - Sylvain Baulande
- Institut Curie, PSL University, Single Cell Initiative, ICGex Next-Generation Sequencing Platform, PSL University, 75005, Paris, France
| | - Olivier Delattre
- Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France
- INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Center, Institut Curie Research Center, Paris, France
| | - Eliane Piaggio
- INSERM U932, Immunity and Cancer, PSL Research University, Institut Curie Research Center, Paris, France
| | - Olivier Ayrault
- CNRS UMR 3347, INSERM U1021, Institut Curie, PSL Research University, Université Paris-Saclay, Orsay, France
| | - Joshua J Waterfall
- INSERM U830, Integrative Functional Genomics of Cancer Lab, PSL Research University, Institut Curie Research Center, Paris, France
- Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France
| | - Nicolas Servant
- INSERM U900, Bioinformatics, Biostatistics, Epidemiology and Computational Systems Unit, Institut Curie, Mines Paris Tech, PSL Research University, Institut Curie Research Center, Paris, France
| | - Kevin Beccaria
- Department of Pediatric Neurosurgery-AP-HP, Necker Sick Kids Hospital, Université de Paris, Paris, France
| | - Volodia Dangouloff-Ros
- Pediatric Radiology Department, AP-HP, Necker Sick Kids Hospital and Paris Cite Universiy INSERM 1299 and UMR 1163, Institut Imagine, Paris, France
| | - Franck Bourdeaut
- INSERM U830, Laboratory of Translational Research In Pediatric Oncology, PSL Research University, SIREDO Oncology center, Institut Curie Research Center, Paris, France.
- Department of Pediatric Oncology, SIREDO Oncology Center, Institut Curie Hospital, Paris, and Université de Paris, Paris, France.
| |
Collapse
|
6
|
Rodriguez C, Araujo Furlan CL, Tosello Boari J, Bossio SN, Boccardo S, Fozzatti L, Canale FP, Beccaria CG, Nuñez NG, Ceschin DG, Piaggio E, Gruppi A, Montes CL, Acosta Rodríguez EV. Interleukin-17 signaling influences CD8 + T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells. Oncoimmunology 2023; 12:2261326. [PMID: 37808403 PMCID: PMC10557545 DOI: 10.1080/2162402x.2023.2261326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Accepted: 09/15/2023] [Indexed: 10/10/2023] Open
Abstract
IL-17 immune responses in cancer are controversial, with both tumor-promoting and tumor-repressing effects observed. To clarify the role of IL-17 signaling in cancer progression, we used syngeneic tumor models from different tissue origins. We found that deficiencies in host IL-17RA or IL-17A/F expression had varying effects on the in vivo growth of different solid tumors including melanoma, sarcoma, lymphoma, and leukemia. In each tumor type, the absence of IL-17 led to changes in the expression of mediators associated with inflammation and metastasis in the tumor microenvironment. Furthermore, IL-17 signaling deficiencies in the hosts resulted in decreased anti-tumor CD8+ T cell immunity and caused tumor-specific changes in several lymphoid cell populations. Our findings were associated with distinct patterns of IL-17A/F cytokine and receptor subunit expression in the injected tumor cell lines. These patterns affected tumor cell responsiveness to IL-17 and downstream intracellular signaling, leading to divergent effects on cancer progression. Additionally, we identified IL-17RC as a critical determinant of the IL-17-mediated response in tumor cells and a potential biomarker for IL-17 signaling effects in tumor progression. Our study offers insight into the molecular mechanisms underlying IL-17 activities in cancer and lays the groundwork for developing personalized immunotherapies.
Collapse
Affiliation(s)
- Constanza Rodriguez
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Cintia L. Araujo Furlan
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Jimena Tosello Boari
- INSERM U932, Immunity and Cancer, Paris, France
- Department of Translational Research, PSL Research University, Paris, France
| | - Sabrina N. Bossio
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Santiago Boccardo
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Laura Fozzatti
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Fernando P. Canale
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Cristian G. Beccaria
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Nicolás G. Nuñez
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Danilo G. Ceschin
- Centro de Investigación en Medicina Traslacional “Severo R. Amuchástegui” (CIMETSA), Vinculado al Instituto de Investigación Médica Mercedes y Martín Ferreyra (CONICET-UNC), Instituto Universitario de Ciencias Biomédicas de Córdoba (IUCBC), Córdoba, Argentina
| | - Eliane Piaggio
- INSERM U932, Immunity and Cancer, Paris, France
- Department of Translational Research, PSL Research University, Paris, France
| | - Adriana Gruppi
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Carolina L. Montes
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Eva V. Acosta Rodríguez
- Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| |
Collapse
|
7
|
Borcoman E, Lalanne A, Delord JP, Cassier PA, Rolland F, Salas S, Limacher JM, Capitain O, Lantz O, Ekwegbara C, Jeannot E, Cyrta J, Tran-Perennou C, Castel-Ajgal Z, Marret G, Piaggio E, Brandely M, Tavernaro A, Makhloufi H, Bendjama K, Le Tourneau C. Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. Eur J Cancer 2023; 191:112981. [PMID: 37506588 DOI: 10.1016/j.ejca.2023.112981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 07/01/2023] [Indexed: 07/30/2023]
Abstract
PURPOSE To evaluate tipapkinogene sovacivec (TG4001), a viral immunotherapeutic vaccine expressing human papillomavirus (HPV)16 E6/E7 non-oncogenic proteins and IL-2, in combination with avelumab in HPV16+ cancer patients. PATIENTS AND METHODS In this open-label, phase Ib/II, multicenter study, HPV16+ advanced cancer patients received subcutaneous TG4001 at two dose levels (DL) in phase Ib and at the recommended phase II dose (RP2D) in phase II weekly for 6 weeks, then every 2 weeks (q2Wk) until 6 months, thereafter every 12 weeks, in combination with avelumab q2Wk starting from day 8. Exploratory end-points included immunomonitoring from sequential tumour and blood samples. RESULTS Forty-three patients, mainly heavily pretreated (88% ≥ 1 previous line), were included in the safety analysis, with a majority of anal cancer (44%). No dose-limiting toxicities were reported, and DL2 (5 × 107 Plaque forming units (PFU)) was selected as the RP2D. Treatment-related adverse events to TG4001 occurred in 93% of patients, mostly grade 1/2, with grade 3 anaemia in one patient and no grade 4/5. Overall response rate (ORR) was 22% (8/36) and 32% (8/25) in all and patients without liver metastases, respectively. Median progression-free survival (PFS) and Overall Survival (OS) were 2.8 months (95% CI: 1.4-5.6) and 11.0 months (95% CI:7.5-16.7) in the total population and 5.6 months (95% CI:1.6-9.6) and 13.3 months (95% CI:8.7-32.7) in patients without liver metastases. Antigen-specific T-cell response was identified in 7/11 patients by IFNγ ELISpot. CONCLUSIONS TG4001 in combination with avelumab is safe, demonstrated antitumour activity in heavily pre-treated HPV16+ cancer patients, and is currently being evaluated in a randomised phase II trial in patients with incurable anogenital cancer and limited hepatic involvement. CLINICALTRIALS GOV IDENTIFIER NCT03260023.
Collapse
Affiliation(s)
- Edith Borcoman
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Translational Immunotherapy Team, Translational Research Department, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France
| | - Ana Lalanne
- INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France; CIC IGR-Curie 1428, Center of Clinical Investigation, Institut Curie, Paris, France
| | - Jean-Pierre Delord
- Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
| | | | - Frédéric Rolland
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint Herblain, France
| | - Sébastien Salas
- CEPCM Hôpital Timone, Marseille, France; Aix Marseille University, Marseille, France
| | - Jean-Marc Limacher
- Department of Medical Oncology, Hôpitaux Civils de Colmar, Colmar, France
| | - Olivier Capitain
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Site Paul Papin, Angers, France
| | - Olivier Lantz
- INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France; CIC IGR-Curie 1428, Center of Clinical Investigation, Institut Curie, Paris, France
| | - Christina Ekwegbara
- INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France; CIC IGR-Curie 1428, Center of Clinical Investigation, Institut Curie, Paris, France
| | | | - Joanna Cyrta
- Department of Pathology and Genetics, Institut Curie, Paris, France
| | | | - Zahra Castel-Ajgal
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - Grégoire Marret
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - Eliane Piaggio
- INSERM U932, Immunity and Cancer, Institut Curie, Paris, France; Translational Immunotherapy Team, Translational Research Department, Institut Curie, Paris, France; Université Paris Sciences Lettres (PSL), Paris, France
| | | | | | | | | | - Christophe Le Tourneau
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U900, Institut Curie, Mines Paris Tech, Saint-Cloud, France; Paris-Saclay University, Paris, France.
| |
Collapse
|
8
|
Bossio SN, Abrate C, Tosello Boari J, Rodriguez C, Canale FP, Ramello MC, Brunotto V, Richer W, Rocha D, Sedlik C, Vincent-Salomon A, Borcoman E, Del Castillo A, Gruppi A, Fernandez E, Acosta Rodríguez EV, Piaggio E, Montes CL. CD39 + conventional CD4 + T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade. Oncoimmunology 2023; 12:2246319. [PMID: 37885970 PMCID: PMC10599196 DOI: 10.1080/2162402x.2023.2246319] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 07/03/2023] [Accepted: 08/05/2023] [Indexed: 10/28/2023] Open
Abstract
Conventional CD4+ T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Here, we describe a subset of tumor-infiltrating Tconv cells characterized by the expression of CD39. In several mouse cancer models, we observed that CD39+ Tconv cells accumulated in tumors but were absent in lymphoid organs. Compared to tumor CD39- counterparts, CD39+ Tconv cells exhibited a cytotoxic and exhausted signature at the transcriptomic level, confirmed by high protein expression of inhibitory receptors and transcription factors related to the exhaustion. Additionally, CD39+ Tconv cells showed increased production of IFNγ , granzyme B, perforin and CD107a expression, but reduced production of TNF. Around 55% of OVA-specific Tconv from B16-OVA tumor-bearing mice, expressed CD39. In vivo CTLA-4 blockade induced the expansion of tumor CD39+ Tconv cells, which maintained their cytotoxic and exhausted features. In breast cancer patients, CD39+ Tconv cells were found in tumors and in metastatic lymph nodes but were less frequent in adjacent non-tumoral mammary tissue and not detected in non-metastatic lymph nodes and blood. Human tumor CD39+ Tconv cells constituted a heterogeneous cell population with features of exhaustion, high expression of inhibitory receptors and CD107a. We found that high CD4 and ENTPD1 (CD39) gene expression in human tumor tissues correlated with a higher overall survival rate in breast cancer patients. Our results identify CD39 as a biomarker of Tconv cells, with characteristics of both exhaustion and cytotoxic potential, and indicate CD39+ Tconv cells as players within the immune response against tumors.
Collapse
Affiliation(s)
- Sabrina N. Bossio
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Carolina Abrate
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Jimena Tosello Boari
- Institut Curie Research Center, Translational Research Department, INSERM U932, PSL Research University, Paris, France
| | - Constanza Rodriguez
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Fernando P. Canale
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - María C. Ramello
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Valentina Brunotto
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Wilfrid Richer
- Institut Curie Research Center, Translational Research Department, INSERM U932, PSL Research University, Paris, France
| | - Dario Rocha
- Centro de Investigación y desarrollo en inmunología y enfermedades infecciosas (CIDIE-CONICET), Argentina
| | - Christine Sedlik
- Institut Curie Research Center, Translational Research Department, INSERM U932, PSL Research University, Paris, France
| | - Anne Vincent-Salomon
- Diagnostic and Theranostic Medicine Division, Institut Curie, PSL Research University, Paris, France
| | - Edith Borcoman
- Department of Medical Oncology, Institut Curie, Paris, France
| | | | - Adriana Gruppi
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Elmer Fernandez
- Centro de Investigación y desarrollo en inmunología y enfermedades infecciosas (CIDIE-CONICET), Argentina
| | - Eva V. Acosta Rodríguez
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Eliane Piaggio
- Institut Curie Research Center, Translational Research Department, INSERM U932, PSL Research University, Paris, France
| | - Carolina L. Montes
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| |
Collapse
|
9
|
Niborski LL, Gueguen P, Ye M, Thiolat A, Ramos RN, Caudana P, Denizeau J, Colombeau L, Rodriguez R, Goudot C, Luccarini JM, Soudé A, Bournique B, Broqua P, Pace L, Baulande S, Sedlik C, Quivy JP, Almouzni G, Cohen JL, Zueva E, Waterfall JJ, Amigorena S, Piaggio E. Author Correction: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas. Nat Commun 2023; 14:3127. [PMID: 37253849 DOI: 10.1038/s41467-023-38931-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Affiliation(s)
- Leticia Laura Niborski
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
- Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Paul Gueguen
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
| | - Mengliang Ye
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
| | - Allan Thiolat
- Université Paris-Est, UMR S955, Université Paris-Est Créteil Val de Marne, Créteil, France
- INSERM, U955, Equipe 21, Créteil, France
| | - Rodrigo Nalio Ramos
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
- Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Pamela Caudana
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
- Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Jordan Denizeau
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
- Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Ludovic Colombeau
- Institut Curie, PSL Research University, CNRS UMR3666, INSERM U1143, Chemical Biology of Cancer, Equipe Labellisée Ligue contre le Cancer, Paris, France
| | - Raphaël Rodriguez
- Institut Curie, PSL Research University, CNRS UMR3666, INSERM U1143, Chemical Biology of Cancer, Equipe Labellisée Ligue contre le Cancer, Paris, France
| | - Christel Goudot
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
| | | | - Anne Soudé
- Inventiva, 50 rue de Dijon, 21121, Daix, France
| | | | | | - Luigia Pace
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
| | - Sylvain Baulande
- Institut Curie, Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, Paris, France
| | - Christine Sedlik
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
- Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Jean-Pierre Quivy
- Institut Curie, PSL Research University, F-75005, Paris, France
- Institut Curie, PSL Research University, CNRS, UMR3664, Equipe Labellisée Ligue contre le Cancer, Paris, France
- Sorbonne Universités, UPMC University Paris 06, CNRS, UMR3664, F-7005, Paris, France
| | - Geneviève Almouzni
- Institut Curie, PSL Research University, F-75005, Paris, France
- Institut Curie, PSL Research University, CNRS, UMR3664, Equipe Labellisée Ligue contre le Cancer, Paris, France
- Sorbonne Universités, UPMC University Paris 06, CNRS, UMR3664, F-7005, Paris, France
| | - José L Cohen
- Université Paris-Est, UMR S955, Université Paris-Est Créteil Val de Marne, Créteil, France
- INSERM, U955, Equipe 21, Créteil, France
| | - Elina Zueva
- Institut Curie, PSL Research University, F-75005, Paris, France
- INSERM U932, F-75005, Paris, France
| | - Joshua J Waterfall
- Institut Curie, PSL Research University, F-75005, Paris, France
- Translational Research Department, Institut Curie, F-75005, Paris, France
- INSERM U830, F-75005, Paris, France
| | - Sebastian Amigorena
- Institut Curie, PSL Research University, F-75005, Paris, France.
- INSERM U932, F-75005, Paris, France.
| | - Eliane Piaggio
- Institut Curie, PSL Research University, F-75005, Paris, France.
- INSERM U932, F-75005, Paris, France.
- Translational Research Department, Institut Curie, F-75005, Paris, France.
| |
Collapse
|
10
|
Jneid B, Bochnakian A, Hoffmann C, Delisle F, Djacoto E, Sirven P, Denizeau J, Sedlik C, Gerber-Ferder Y, Fiore F, Akyol R, Brousse C, Kramer R, Walters I, Carlioz S, Salmon H, Malissen B, Dalod M, Piaggio E, Manel N. Selective STING stimulation in dendritic cells primes antitumor T cell responses. Sci Immunol 2023; 8:eabn6612. [PMID: 36638189 DOI: 10.1126/sciimmunol.abn6612] [Citation(s) in RCA: 21] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
T cells that recognize tumor antigens are crucial for mounting antitumor immune responses. Induction of antitumor T cells in immunogenic tumors depends on STING, the intracellular innate immune receptor for cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and related cyclic dinucleotides (CDNs). However, the optimal way to leverage STING activation in nonimmunogenic tumors is still unclear. Here, we show that cGAMP delivery by intratumoral injection of virus-like particles (cGAMP-VLP) led to differentiation of circulating tumor-specific T cells, decreased tumor regulatory T cells (Tregs), and antitumoral responses that synergized with PD1 blockade. By contrast, intratumoral injection of the synthetic CDN ADU-S100 led to tumor necrosis and systemic T cell activation but simultaneously depleted immune cells from injected tumors and induced minimal priming of circulating tumor-specific T cells. The antitumor effects of cGAMP-VLP required type 1 conventional dendritic cells (cDC1), whereas ADU-S100 eliminated cDC1 from injected tumors. cGAMP-VLP preferentially targeted STING in dendritic cells at a 1000-fold smaller dose than ADU-S100. Subcutaneous administration of cGAMP-VLP showed synergy when combined with PD1 blockade or a tumor Treg-depleting antibody to elicit systemic tumor-specific T cells and antitumor activity, leading to complete and durable tumor eradication in the case of tumor Treg depletion. These findings show that cell targeting of STING stimulation shapes the antitumor T cell response and identify a therapeutic strategy to enhance T cell-targeted immunotherapy.
Collapse
Affiliation(s)
- Bakhos Jneid
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Aurore Bochnakian
- Institut Curie, PSL Research University, INSERM U932, Paris, France.,Stimunity, Paris, France
| | - Caroline Hoffmann
- Institut Curie, INSERM U932 Immunity and Cancer, Department of Surgical Oncology, PSL University, Paris, France
| | - Fabien Delisle
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Emeline Djacoto
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Philémon Sirven
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Jordan Denizeau
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Christine Sedlik
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | | | - Frédéric Fiore
- Centre d'Immunophénomique (CIPHE), Aix Marseille Université, INSERM, CNRS, 13288 Marseille, France
| | - Ramazan Akyol
- Aix-Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France
| | - Carine Brousse
- Aix-Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France
| | | | | | | | - Hélène Salmon
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Bernard Malissen
- Centre d'Immunophénomique (CIPHE), Aix Marseille Université, INSERM, CNRS, 13288 Marseille, France
| | - Marc Dalod
- Aix-Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Nicolas Manel
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| |
Collapse
|
11
|
Niborski LL, Gueguen P, Ye M, Thiolat A, Ramos RN, Caudana P, Denizeau J, Colombeau L, Rodriguez R, Goudot C, Luccarini JM, Soudé A, Bournique B, Broqua P, Pace L, Baulande S, Sedlik C, Quivy JP, Almouzni G, Cohen JL, Zueva E, Waterfall JJ, Amigorena S, Piaggio E. CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas. Nat Commun 2022; 13:3739. [PMID: 35768432 PMCID: PMC9243005 DOI: 10.1038/s41467-022-31504-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 06/18/2022] [Indexed: 11/09/2022] Open
Abstract
Tumor-infiltrating CD8 + T cells progressively lose functionality and fail to reject tumors. The underlying mechanism and re-programing induced by checkpoint blockers are incompletely understood. We show here that genetic ablation or pharmacological inhibition of histone lysine methyltransferase Suv39h1 delays tumor growth and potentiates tumor rejection by anti-PD-1. In the absence of Suv39h1, anti-PD-1 induces alternative activation pathways allowing survival and differentiation of IFNγ and Granzyme B producing effector cells that express negative checkpoint molecules, but do not reach final exhaustion. Their transcriptional program correlates with that of melanoma patients responding to immune-checkpoint blockade and identifies the emergence of cytolytic-effector tumor-infiltrating lymphocytes as a biomarker of clinical response. Anti-PD-1 favors chromatin opening in loci linked to T-cell activation, memory and pluripotency, but in the absence of Suv39h1, cells acquire accessibility in cytolytic effector loci. Overall, Suv39h1 inhibition enhances anti-tumor immune responses, alone or combined with anti-PD-1, suggesting that Suv39h1 is an “epigenetic checkpoint” for tumor immunity. Understanding CD8 + T cell response to immune checkpoint blockade at the molecular level is important for the design of more efficient cancer immune therapies. Authors show here that the histone lysine methyltransferase Suv39h1 controls the transcriptional programs that determine the functionality of CD8 + T cells and Suv39h1 inhibition may potentiate anti-PD-1 therapy of melanomas.
Collapse
Affiliation(s)
- Leticia Laura Niborski
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France.,Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Paul Gueguen
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France
| | - Mengliang Ye
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France
| | - Allan Thiolat
- Université Paris-Est, UMR S955, Université Paris-Est Créteil Val de Marne, Créteil, France.,INSERM, U955, Equipe 21, Créteil, France
| | - Rodrigo Nalio Ramos
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France.,Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Pamela Caudana
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France.,Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Jordan Denizeau
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France.,Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Ludovic Colombeau
- Institut Curie, PSL Research University, CNRS UMR3666, INSERM U1143, Chemical Biology of Cancer, Equipe Labellisée Ligue contre le Cancer, Paris, France
| | - Raphaël Rodriguez
- Institut Curie, PSL Research University, CNRS UMR3666, INSERM U1143, Chemical Biology of Cancer, Equipe Labellisée Ligue contre le Cancer, Paris, France
| | - Christel Goudot
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France
| | | | - Anne Soudé
- Inventiva, 50 rue de Dijon, 21121, Daix, France
| | | | | | - Luigia Pace
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France
| | - Sylvain Baulande
- Institut Curie, Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, Paris, France
| | - Christine Sedlik
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France.,Translational Research Department, Institut Curie, F-75005, Paris, France
| | - Jean-Pierre Quivy
- Institut Curie, PSL Research University, F-75005, Paris, France.,Institut Curie, PSL Research University, CNRS, UMR3664, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Sorbonne Universités, UPMC University Paris 06, CNRS, UMR3664, F-7005, Paris, France
| | - Geneviève Almouzni
- Institut Curie, PSL Research University, F-75005, Paris, France.,Institut Curie, PSL Research University, CNRS, UMR3664, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Sorbonne Universités, UPMC University Paris 06, CNRS, UMR3664, F-7005, Paris, France
| | - José L Cohen
- Université Paris-Est, UMR S955, Université Paris-Est Créteil Val de Marne, Créteil, France.,INSERM, U955, Equipe 21, Créteil, France
| | - Elina Zueva
- Institut Curie, PSL Research University, F-75005, Paris, France.,INSERM U932, F-75005, Paris, France
| | - Joshua J Waterfall
- Institut Curie, PSL Research University, F-75005, Paris, France.,Translational Research Department, Institut Curie, F-75005, Paris, France.,INSERM U830, F-75005, Paris, France
| | - Sebastian Amigorena
- Institut Curie, PSL Research University, F-75005, Paris, France. .,INSERM U932, F-75005, Paris, France.
| | - Eliane Piaggio
- Institut Curie, PSL Research University, F-75005, Paris, France. .,INSERM U932, F-75005, Paris, France. .,Translational Research Department, Institut Curie, F-75005, Paris, France.
| |
Collapse
|
12
|
Ramos RN, Tosch C, Kotsias F, Claudepierre MC, Schmitt D, Remy-Ziller C, Hoffmann C, Ricordel M, Nourtier V, Farine I, Laruelle L, Hortelano J, Spring-Giusti C, Sedlik C, Le Tourneau C, Hoffmann C, Silvestre N, Erbs P, Bendjama K, Thioudellet C, Quemeneur E, Piaggio E, Rittner K. Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination. Clin Transl Immunology 2022; 11:e1392. [PMID: 35573979 PMCID: PMC9081486 DOI: 10.1002/cti2.1392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 01/11/2022] [Accepted: 04/16/2022] [Indexed: 11/11/2022] Open
Abstract
Objective Antitumor viral vaccines, and more particularly poxviral vaccines, represent an active field for clinical development and translational research. To improve the efficacy and treatment outcome, new viral vectors are sought, with emphasis on their abilities to stimulate innate immunity, to display tumor antigens and to induce a specific T‐cell response. Methods We screened for a new poxviral backbone with improved innate and adaptive immune stimulation using IFN‐α secretion levels in infected PBMC cultures as selection criteria. Assessment of virus effectiveness was made in vitro and in vivo. Results The bovine pseudocowpox virus (PCPV) stood out among several poxviruses for its ability to induce significant secretion of IFN‐α. PCPV produced efficient activation of human monocytes and dendritic cells, degranulation of NK cells and reversed MDSC‐induced T‐cell suppression, without being offensive to activated T cells. A PCPV‐based vaccine, encoding the HPV16 E7 protein (PCPV‐E7), stimulated strong antigen‐specific T‐cell responses in TC1 tumor‐bearing mice. Complete regression of tumors was obtained in a CD8+ T‐cell‐dependent manner after intratumoral injection of PCPV‐E7, followed by intravenous injection of the cancer vaccine MVA‐E7. PCPV also proved active when injected repeatedly intratumorally in MC38 tumor‐bearing mice, generating tumor‐specific T‐cell responses without encoding a specific MC38 antigen. From a translational perspective, we demonstrated that PCPV‐E7 effectively stimulated IFN‐γ production by T cells from tumor‐draining lymph nodes of HPV+‐infected cancer patients. Conclusion We propose PCPV as a viral vector suitable for vaccination in the field of personalised cancer vaccines, in particular for heterologous prime‐boost regimens.
Collapse
Affiliation(s)
- Rodrigo Nalio Ramos
- Institut Curie INSERM U932, and Centre d'Investigation Clinique Biotherapie CICBT 1428 PSL Research University Paris France.,Present address: Laboratório de Investigação Médica em Patogênese e Terapia dirigida em Onco-Imuno-Hematologia Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo (HCFMUSP) São Paulo Brazil.,Present address: Instituto D'Or de Ensino e Pesquisa São Paulo Brazil
| | | | - Fiorella Kotsias
- Institut Curie INSERM U932, and Centre d'Investigation Clinique Biotherapie CICBT 1428 PSL Research University Paris France
| | | | | | | | | | | | | | | | | | | | | | - Christine Sedlik
- Institut Curie INSERM U932, and Centre d'Investigation Clinique Biotherapie CICBT 1428 PSL Research University Paris France
| | - Christophe Le Tourneau
- Department of Drug Development and Innovation (D3i) Institut Curie Paris and Saint-Cloud France
| | - Caroline Hoffmann
- Institut Curie INSERM U932, and Centre d'Investigation Clinique Biotherapie CICBT 1428 PSL Research University Paris France.,Department of Surgical Oncology Institut Curie PSL Research University Paris France
| | | | | | | | | | | | - Eliane Piaggio
- Institut Curie INSERM U932, and Centre d'Investigation Clinique Biotherapie CICBT 1428 PSL Research University Paris France
| | | |
Collapse
|
13
|
Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Núñez NG, Tosello Boari J, Richer W, Menger L, Denizeau J, Sedlik C, Caudana P, Kotsias F, Niborski LL, Viel S, Bohec M, Lameiras S, Baulande S, Lesage L, Nicolas A, Meseure D, Vincent-Salomon A, Reyal F, Dutertre CA, Ginhoux F, Vimeux L, Donnadieu E, Buttard B, Galon J, Zelenay S, Vermi W, Guermonprez P, Piaggio E, Helft J. Tissue-resident FOLR2 + macrophages associate with CD8 + T cell infiltration in human breast cancer. Cell 2022; 185:1189-1207.e25. [PMID: 35325594 DOI: 10.1016/j.cell.2022.02.021] [Citation(s) in RCA: 137] [Impact Index Per Article: 68.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 10/08/2021] [Accepted: 02/15/2022] [Indexed: 12/12/2022]
Abstract
Macrophage infiltration is a hallmark of solid cancers, and overall macrophage infiltration correlates with lower patient survival and resistance to therapy. Tumor-associated macrophages, however, are phenotypically and functionally heterogeneous. Specific subsets of tumor-associated macrophage might be endowed with distinct roles on cancer progression and antitumor immunity. Here, we identify a discrete population of FOLR2+ tissue-resident macrophages in healthy mammary gland and breast cancer primary tumors. FOLR2+ macrophages localize in perivascular areas in the tumor stroma, where they interact with CD8+ T cells. FOLR2+ macrophages efficiently prime effector CD8+ T cells ex vivo. The density of FOLR2+ macrophages in tumors positively correlates with better patient survival. This study highlights specific roles for tumor-associated macrophage subsets and paves the way for subset-targeted therapeutic interventions in macrophages-based cancer therapies.
Collapse
Affiliation(s)
- Rodrigo Nalio Ramos
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Yoann Missolo-Koussou
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Yohan Gerber-Ferder
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Christian P Bromley
- Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, UK
| | - Mattia Bugatti
- Department of Pathology, University of Brescia, Brescia 25123, Italy
| | - Nicolas Gonzalo Núñez
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Jimena Tosello Boari
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Wilfrid Richer
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Laurie Menger
- PSL University, Institut Curie Research Center, INSERM U932, 75005 Paris, France
| | - Jordan Denizeau
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Christine Sedlik
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Pamela Caudana
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Fiorella Kotsias
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Leticia L Niborski
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Sophie Viel
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Mylène Bohec
- PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France
| | - Sonia Lameiras
- PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France
| | - Sylvain Baulande
- PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France
| | - Laëtitia Lesage
- PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France
| | - André Nicolas
- PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France
| | - Didier Meseure
- PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France
| | - Anne Vincent-Salomon
- PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France
| | - Fabien Reyal
- PSL University, Institut Curie Hospital, Department of Surgery, 75005 Paris, France
| | | | - Florent Ginhoux
- Université Paris-Saclay, Institut Gustave Roussy, INSERM U1015, Villejuif, France; Singapore Immunology Network, Agency for Science, Technology and Research, Singapore 138648, Singapore
| | - Lene Vimeux
- University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France
| | - Emmanuel Donnadieu
- University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France
| | - Bénédicte Buttard
- INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology, Paris, France
| | - Jérôme Galon
- INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology, Paris, France
| | - Santiago Zelenay
- Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, UK
| | - William Vermi
- PSL University, Institut Curie Research Center, INSERM U932, 75005 Paris, France; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Pierre Guermonprez
- Université de Paris, Centre for Inflammation Research, CNRS ERL8252, INSERM1149, Paris, France
| | - Eliane Piaggio
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France
| | - Julie Helft
- PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
| |
Collapse
|
14
|
Rethacker L, Boy M, Bisio V, Roussin F, Denizeau J, Vincent-Salomon A, Borcoman E, Sedlik C, Piaggio E, Toubert A, Dulphy N, Caignard A. Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes. Oncoimmunology 2022; 11:2057396. [PMID: 35371620 PMCID: PMC8973349 DOI: 10.1080/2162402x.2022.2057396] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Innate lymphoid cells (ILCs) – which include cytotoxic Natural Killer (NK) cells and helper-type ILC – are important regulators of tissue immune homeostasis, with possible roles in tumor surveillance. We analyzed ILC and their functionality in human lymph nodes (LN). In LN, NK cells and ILC3 were the prominent subpopulations. Among the ILC3s, we identified a CD56+/ILC3 subset with a phenotype close to ILC3 but also expressing cytotoxicity genes shared with NK. In tumor-draining LNs (TD-LNs) and tumor samples from breast cancer (BC) patients, NK cells were prominent, and proportions of ILC3 subsets were low. In tumors and TD-LN, NK cells display reduced levels of NCR (Natural cytotoxicity receptors), despite high transcript levels and included a small subset CD127− CD56− NK cells with reduced function. Activated by cytokines CD56+/ILC3 cells from donor and patients LN acquired cytotoxic capacity and produced IFNg. In TD-LN, all cytokine activated ILC populations produced TNFα in response to BC cell line. Analyses of cytotoxic and helper ILC indicate a switch toward NK cells in TD-LN. The local tumor microenvironment inhibited NK cell functions through downregulation of NCR, but cytokine stimulation restored their functionality.
Collapse
Affiliation(s)
- Louise Rethacker
- INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France
| | - Maxime Boy
- INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France
| | - Valeria Bisio
- INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France
| | - France Roussin
- Service d’Anesthésie-Réanimation, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Jordan Denizeau
- INSERM U932, Département de Recherche Translationelle, Institut Curie, Université de Recherche Paris Sciences & Lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
| | - Anne Vincent-Salomon
- Diagnostic and Theranostic Medicine Division, Institut Curie, PSL Research University, Paris, France
| | - Edith Borcoman
- Department of Medical Oncology, Institut Curie, Paris, France
- Université Paris Diderot, Université de Paris, Paris, France
| | - Christine Sedlik
- INSERM U932, Département de Recherche Translationelle, Institut Curie, Université de Recherche Paris Sciences & Lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
| | - Eliane Piaggio
- INSERM U932, Département de Recherche Translationelle, Institut Curie, Université de Recherche Paris Sciences & Lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
| | - Antoine Toubert
- INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France
- Université Paris Diderot, Université de Paris, Paris, France
- Assistance Publique–Hôpitaux de Paris (AP–HP), Hôpital Saint-Louis, Laboratoire d’Immunologie et Histocompatibilité, Paris, France
| | - Nicolas Dulphy
- INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France
- Université Paris Diderot, Université de Paris, Paris, France
- Assistance Publique–Hôpitaux de Paris (AP–HP), Hôpital Saint-Louis, Laboratoire d’Immunologie et Histocompatibilité, Paris, France
| | - Anne Caignard
- INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France
| |
Collapse
|
15
|
Paillet J, Plantureux C, Lévesque S, Le Naour J, Stoll G, Sauvat A, Caudana P, Tosello Boari J, Bloy N, Lachkar S, Martins I, Opolon P, Checcoli A, Delaune A, Robil N, de la Grange P, Hamroune J, Letourneur F, Autret G, Leung PS, Gershwin ME, Zhu JS, Kurth MJ, Lekbaby B, Augustin J, Kim Y, Gujar S, Coulouarn C, Fouassier L, Zitvogel L, Piaggio E, Housset C, Soussan P, Maiuri MC, Kroemer G, Pol JG. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. J Exp Med 2021; 218:e20200853. [PMID: 34495298 PMCID: PMC8429038 DOI: 10.1084/jem.20200853] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 06/17/2021] [Accepted: 08/09/2021] [Indexed: 12/12/2022] Open
Abstract
Cholangiocarcinoma (CCA) results from the malignant transformation of cholangiocytes. Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are chronic diseases in which cholangiocytes are primarily damaged. Although PSC is an inflammatory condition predisposing to CCA, CCA is almost never found in the autoimmune context of PBC. Here, we hypothesized that PBC might favor CCA immunosurveillance. In preclinical murine models of cholangitis challenged with syngeneic CCA, PBC (but not PSC) reduced the frequency of CCA development and delayed tumor growth kinetics. This PBC-related effect appeared specific to CCA as it was not observed against other cancers, including hepatocellular carcinoma. The protective effect of PBC was relying on type 1 and type 2 T cell responses and, to a lesser extent, on B cells. Single-cell TCR/RNA sequencing revealed the existence of TCR clonotypes shared between the liver and CCA tumor of a PBC host. Altogether, these results evidence a mechanistic overlapping between autoimmunity and cancer immunosurveillance in the biliary tract.
Collapse
Affiliation(s)
- Juliette Paillet
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
- Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France
| | - Céleste Plantureux
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
- Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France
| | - Sarah Lévesque
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
- Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France
| | - Julie Le Naour
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
- Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France
| | - Gautier Stoll
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
| | - Allan Sauvat
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
| | - Pamela Caudana
- Institut Curie, Paris Sciences et Lettres Research University, Institut National de la Santé et de la Recherche Médicale U932, Paris, France
| | - Jimena Tosello Boari
- Institut Curie, Paris Sciences et Lettres Research University, Institut National de la Santé et de la Recherche Médicale U932, Paris, France
| | - Norma Bloy
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
- Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France
| | - Sylvie Lachkar
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
| | - Isabelle Martins
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Andrea Checcoli
- Institut Curie, Paris Sciences et Lettres Research University, Paris, France
- Institut National de la Santé et de la Recherche Médicale U900, Paris, France
| | | | | | | | - Juliette Hamroune
- Institut National de la Santé et de la Recherche Médicale U1016, Institut Cochin, Paris, France
| | - Franck Letourneur
- Institut National de la Santé et de la Recherche Médicale U1016, Institut Cochin, Paris, France
| | - Gwennhael Autret
- Université de Paris, Paris Cardiovascular Research Centre, Institut National de la Santé et de la Recherche Médicale U970, Paris, France
| | - Patrick S.C. Leung
- Division of Rheumatology/Allergy and Clinical Immunology, University of California, Davis School of Medicine, Davis, CA
| | - M. Eric Gershwin
- Division of Rheumatology/Allergy and Clinical Immunology, University of California, Davis School of Medicine, Davis, CA
| | - Jie S. Zhu
- Department of Chemistry, University of California, Davis, Davis, CA
| | - Mark J. Kurth
- Department of Chemistry, University of California, Davis, Davis, CA
| | - Bouchra Lekbaby
- Institut National de la Santé et de la Recherche Médicale U938, Centre de Recherche Saint-Antoine, Sorbonne Université, Paris, France
| | - Jérémy Augustin
- Institut National de la Santé et de la Recherche Médicale U938, Centre de Recherche Saint-Antoine, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Département de Pathologie, Paris, France
| | - Youra Kim
- Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Shashi Gujar
- Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada
- Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada
- Department of Biology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Cédric Coulouarn
- Institut National de la Santé et de la Recherche Médicale, Université de Rennes 1, Chemistry, Oncogenesis Stress Signaling, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France
| | - Laura Fouassier
- Institut National de la Santé et de la Recherche Médicale U938, Centre de Recherche Saint-Antoine, Sorbonne Université, Paris, France
| | - Laurence Zitvogel
- Institut National de la Santé et de la Recherche Médicale U1015, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France
| | - Eliane Piaggio
- Centre d'Investigation Clinique Biothérapie 1428, Institut Curie, Paris, France
| | - Chantal Housset
- Institut National de la Santé et de la Recherche Médicale U938, Centre de Recherche Saint-Antoine, Sorbonne Université, Paris, France
- Assistance Publique-Hôpitaux de Paris, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, Department of Hepatology, Saint-Antoine Hospital, Paris, France
| | - Patrick Soussan
- Institut National de la Santé et de la Recherche Médicale U938, Centre de Recherche Saint-Antoine, Sorbonne Université, Paris, France
| | - Maria Chiara Maiuri
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
| | - Guido Kroemer
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
- Institut Universitaire de France, Paris, France
- Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
- Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China
- Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden
| | - Jonathan G. Pol
- Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale U1138, Université de Paris, Sorbonne Université, Paris, France
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
16
|
Ramello MC, Núñez NG, Tosello Boari J, Bossio SN, Canale FP, Abrate C, Ponce N, Del Castillo A, Ledesma M, Viel S, Richer W, Sedlik C, Tiraboschi C, Muñoz M, Compagno D, Gruppi A, Acosta Rodríguez EV, Piaggio E, Montes CL. Polyfunctional KLRG-1 +CD57 + Senescent CD4 + T Cells Infiltrate Tumors and Are Expanded in Peripheral Blood From Breast Cancer Patients. Front Immunol 2021; 12:713132. [PMID: 34386013 PMCID: PMC8353459 DOI: 10.3389/fimmu.2021.713132] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Accepted: 07/05/2021] [Indexed: 01/19/2023] Open
Abstract
Senescent T cells have been described during aging, chronic infections, and cancer; however, a comprehensive study of the phenotype, function, and transcriptional program of this T cell population in breast cancer (BC) patients is missing. Compared to healthy donors (HDs), BC patients exhibit an accumulation of KLRG-1+CD57+ CD4+ and CD8+ T cells in peripheral blood. These T cells infiltrate tumors and tumor-draining lymph nodes. KLRG-1+CD57+ CD4+ and CD8+ T cells from BC patients and HDs exhibit features of senescence, and despite their inhibitory receptor expression, they produce more effector cytokines and exhibit higher expression of Perforin, Granzyme B, and CD107a than non-senescent subsets. When compared to blood counterparts, tumor-infiltrating senescent CD4+ T cells show similar surface phenotype but reduced cytokine production. Transcriptional profiling of senescent CD4+ T cells from the peripheral blood of BC patients reveals enrichment in genes associated with NK or CD8+-mediated cytotoxicity, TCR-mediated stimulation, and cell exhaustion compared to non-senescent T cells. Comparison of the transcriptional profile of senescent CD4+ T cells from peripheral blood of BC patients with those of HDs highlighted marked similarities but also relevant differences. Senescent CD4+ T cells from BC patients show enrichment in T-cell signaling, processes involved in DNA replication, p53 pathways, oncogene-induced senescence, among others compared to their counterparts in HDs. High gene expression of CD4, KLRG-1, and B3GAT1 (CD57), which correlates with increased overall survival for BC patients, underscores the usefulness of the evaluation of the frequency of senescent CD4+ T cells as a biomarker in the follow-up of patients.
Collapse
Affiliation(s)
- Maria C Ramello
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Nicolás G Núñez
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; INSERM U932, Paris, France
| | - Jimena Tosello Boari
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina.,PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; INSERM U932, Paris, France
| | - Sabrina N Bossio
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Fernando P Canale
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Carolina Abrate
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Nicolas Ponce
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | | | - Marta Ledesma
- Gynecology Deparment, Hospital Rawson, Córdoba, Argentina
| | - Sophie Viel
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; INSERM U932, Paris, France
| | - Wilfrid Richer
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; INSERM U932, Paris, France
| | - Christine Sedlik
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; INSERM U932, Paris, France
| | - Carolina Tiraboschi
- Laboratory of Molecular and Functional Glyco-Oncology, IQUIBICEN-CONICET-UBA, CABA (Ciudad Autónoma de Buenos Aires), Argentina
| | - Marcos Muñoz
- Laboratorio de Medicina experimental y terapéutica, IMIBIO, Universidad Nacional de San Luis, San Luis, Argentina
| | - Daniel Compagno
- Laboratory of Molecular and Functional Glyco-Oncology, IQUIBICEN-CONICET-UBA, CABA (Ciudad Autónoma de Buenos Aires), Argentina
| | - Adriana Gruppi
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Eva V Acosta Rodríguez
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| | - Eliane Piaggio
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; INSERM U932, Paris, France
| | - Carolina L Montes
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina
| |
Collapse
|
17
|
Kumar S, Fonseca VR, Ribeiro F, Basto AP, Água-Doce A, Monteiro M, Elessa D, Miragaia RJ, Gomes T, Piaggio E, Segura E, Gama-Carvalho M, Teichmann SA, Graca L. Developmental bifurcation of human T follicular regulatory cells. Sci Immunol 2021; 6:6/59/eabd8411. [PMID: 34049865 DOI: 10.1126/sciimmunol.abd8411] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2020] [Revised: 02/22/2021] [Accepted: 04/29/2021] [Indexed: 12/20/2022]
Abstract
Germinal centers (GCs) are anatomic structures where B cells undergo affinity maturation, leading to production of high-affinity antibodies. The balance between T follicular helper (TFH) and regulatory (TFR) cells is critical for adequate control of GC responses. The study of human TFH and TFR cell development has been hampered because of the lack of in vitro assays reproducing in vivo biology, along with difficult access to healthy human lymphoid tissues. We used a single-cell transcriptomics approach to study the maturation of TFH and TFR cells isolated from human blood, iliac lymph nodes (LNs), and tonsils. As independent tissues have distinct proportions of follicular T cells in different maturation states, we leveraged the heterogeneity to reconstruct the maturation trajectory for human TFH and TFR cells. We found that the dominant maturation of TFR cells follows a bifurcated trajectory from precursor Treg cells, with one arm of the bifurcation leading to blood TFR cells and the other leading to the most mature GC TFR cells. Overall, our data provide a comprehensive resource for the transcriptomics of different follicular T cell populations and their dynamic relationship across different tissues.
Collapse
Affiliation(s)
- Saumya Kumar
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.,Instituto Gulbenkian de Ciência, Oeiras, Portugal
| | - Válter R Fonseca
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.,Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal
| | - Filipa Ribeiro
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.,Instituto Gulbenkian de Ciência, Oeiras, Portugal
| | - Afonso P Basto
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.,Instituto Gulbenkian de Ciência, Oeiras, Portugal
| | - Ana Água-Doce
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.,Instituto Gulbenkian de Ciência, Oeiras, Portugal
| | | | - Dikélélé Elessa
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Ricardo J Miragaia
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK
| | - Tomás Gomes
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris F-75005, France.,Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Elodie Segura
- Institut Curie, PSL Research University, INSERM U932, Paris F-75005, France
| | - Margarida Gama-Carvalho
- BioISI - Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisbon, Lisboa 1749-016, Portugal
| | - Sarah A Teichmann
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.,Theory of Condensed Matter Group, Cavendish Laboratory/Department of Physics, University of Cambridge, JJ Thomson Ave., Cambridge CB3 0HE, UK
| | - Luis Graca
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. .,Instituto Gulbenkian de Ciência, Oeiras, Portugal
| |
Collapse
|
18
|
Abstract
Immunotherapy is at the forefront of cancer treatment. The advent of numerous novel approaches to cancer immunotherapy, including immune checkpoint antibodies, adoptive transfer of CAR (chimeric antigen receptor) T cells and TCR (T cell receptor) T cells, NK (natural killer) cells, T cell engagers, oncolytic viruses, and vaccines, is revolutionizing the treatment for different tumor types. Some are already in the clinic, and many others are underway. However, not all patients respond, resistance develops, and as available therapies multiply there is a need to further understand how they work, how to prioritize their clinical evaluation, and how to combine them. For this, animal models have been highly instrumental, and humanized mice models (i.e., immunodeficient mice engrafted with human immune and cancer cells) represent a step forward, although they have several limitations. Here, we review the different humanized models available today, the approaches to overcome their flaws, their use for the evaluation of cancer immunotherapies, and their anticipated evolution as tools to help personalized clinical decision-making.
Collapse
Affiliation(s)
- Silvia Guil-Luna
- Maimónides Institute for Biomedical Research of Córdoba (IMIBIC), 14004 Córdoba, Spain
| | - Christine Sedlik
- Translational Research Department, Institut Curie Research Center, INSERM U932, PSL Research University, 75248 Paris, France;,
| | - Eliane Piaggio
- Translational Research Department, Institut Curie Research Center, INSERM U932, PSL Research University, 75248 Paris, France;,
| |
Collapse
|
19
|
Leruste A, Chauvin C, Pouponnot C, Bourdeaut F, Waterfall JJ, Piaggio E. Immune responses in genomically simple SWI/SNF-deficient cancers. Cancer 2020; 127:172-180. [PMID: 33079397 DOI: 10.1002/cncr.33172] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Revised: 06/27/2020] [Accepted: 07/23/2020] [Indexed: 01/09/2023]
Affiliation(s)
- Amaury Leruste
- Translational Research in Pediatric Oncology (RTOP) team, INSERM U830, Curie Institute Research Center, PSL Research University, Paris, France.,SIREDO Pediatric Cancer Center, Curie Institute, Paris, France.,Translational Research Department, Curie Institute Research Center, PSL Research University, Paris, France
| | - Céline Chauvin
- Translational Research in Pediatric Oncology (RTOP) team, INSERM U830, Curie Institute Research Center, PSL Research University, Paris, France.,SIREDO Pediatric Cancer Center, Curie Institute, Paris, France.,Translational Research Department, Curie Institute Research Center, PSL Research University, Paris, France
| | - Celio Pouponnot
- CNRS UMR 3347, INSERM U1021, Curie Institute Research Center, PSL Research University, Orsay, France
| | - Franck Bourdeaut
- Translational Research in Pediatric Oncology (RTOP) team, INSERM U830, Curie Institute Research Center, PSL Research University, Paris, France.,SIREDO Pediatric Cancer Center, Curie Institute, Paris, France.,Translational Research Department, Curie Institute Research Center, PSL Research University, Paris, France
| | - Joshua J Waterfall
- Translational Research Department, Curie Institute Research Center, PSL Research University, Paris, France.,Integrative Functional Genomics of Cancer (IFGC) team, INSERM U830, Curie Institute Research Center, PSL Research University, Paris, France
| | - Eliane Piaggio
- Translational Research Department, Curie Institute Research Center, PSL Research University, Paris, France.,Translational Immunotherapy (TransImm) team, INSERM U932, Curie Institute Research Center, PSL Research University, Paris, France
| |
Collapse
|
20
|
Bourdely P, Anselmi G, Vaivode K, Ramos RN, Missolo-Koussou Y, Hidalgo S, Tosselo J, Nuñez N, Richer W, Vincent-Salomon A, Saxena A, Wood K, Lladser A, Piaggio E, Helft J, Guermonprez P. Transcriptional and Functional Analysis of CD1c + Human Dendritic Cells Identifies a CD163 + Subset Priming CD8 +CD103 + T Cells. Immunity 2020; 53:335-352.e8. [PMID: 32610077 PMCID: PMC7445430 DOI: 10.1016/j.immuni.2020.06.002] [Citation(s) in RCA: 179] [Impact Index Per Article: 44.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Revised: 04/15/2020] [Accepted: 05/29/2020] [Indexed: 02/04/2023]
Abstract
Dendritic cells (DCs) are antigen-presenting cells controlling T cell activation. In humans, the diversity, ontogeny, and functional capabilities of DC subsets are not fully understood. Here, we identified circulating CD88-CD1c+CD163+ DCs (called DC3s) as immediate precursors of inflammatory CD88-CD14+CD1c+CD163+FcεRI+ DCs. DC3s develop via a specific pathway activated by GM-CSF, independent of cDC-restricted (CDP) and monocyte-restricted (cMoP) progenitors. Like classical DCs but unlike monocytes, DC3s drove activation of naive T cells. In vitro, DC3s displayed a distinctive ability to prime CD8+ T cells expressing a tissue homing signature and the epithelial homing alpha-E integrin (CD103) through transforming growth factor β (TGF-β) signaling. In vivo, DC3s infiltrated luminal breast cancer primary tumors, and DC3 infiltration correlated positively with CD8+CD103+CD69+ tissue-resident memory T cells. Together, these findings define DC3s as a lineage of inflammatory DCs endowed with a strong potential to regulate tumor immunity.
Collapse
Affiliation(s)
- Pierre Bourdely
- Centre for Inflammation Biology and Cancer Immunology, The Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, UK; Cancer Research UK King's Health Partner Cancer Centre, King's College London, London, UK
| | - Giorgio Anselmi
- Centre for Inflammation Biology and Cancer Immunology, The Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, UK; Cancer Research UK King's Health Partner Cancer Centre, King's College London, London, UK
| | - Kristine Vaivode
- Centre for Inflammation Biology and Cancer Immunology, The Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, UK; Cancer Research UK King's Health Partner Cancer Centre, King's College London, London, UK
| | - Rodrigo Nalio Ramos
- PSL Research University, Institut Curie Research Center, Translational Immunotherapy Team, INSERM U932, Paris, France
| | - Yoann Missolo-Koussou
- PSL Research University, Institut Curie Research Center, Translational Immunotherapy Team, INSERM U932, Paris, France
| | - Sofia Hidalgo
- PSL Research University, Institut Curie Research Center, Translational Immunotherapy Team, INSERM U932, Paris, France; Laboratory of Immuno-oncology, Fundación Ciencia & Vida, Santiago, Chile
| | - Jimena Tosselo
- PSL Research University, Institut Curie Research Center, Translational Immunotherapy Team, INSERM U932, Paris, France
| | - Nicolas Nuñez
- PSL Research University, Institut Curie Research Center, Translational Immunotherapy Team, INSERM U932, Paris, France
| | - Wilfrid Richer
- PSL Research University, Institut Curie Research Center, Translational Immunotherapy Team, INSERM U932, Paris, France
| | - Anne Vincent-Salomon
- PSL Research University, Institut Curie, Department of Biopathology, Paris, France
| | - Alka Saxena
- National Institute of Health Research Biomedical Research Centre at Guy's and St Thomas' Hospital and King's College London, London, UK
| | - Kristie Wood
- National Institute of Health Research Biomedical Research Centre at Guy's and St Thomas' Hospital and King's College London, London, UK
| | - Alvaro Lladser
- Laboratory of Immuno-oncology, Fundación Ciencia & Vida, Santiago, Chile; Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile
| | - Eliane Piaggio
- PSL Research University, Institut Curie Research Center, Translational Immunotherapy Team, INSERM U932, Paris, France
| | - Julie Helft
- PSL Research University, Institut Curie Research Center, Translational Immunotherapy Team, INSERM U932, Paris, France
| | - Pierre Guermonprez
- Centre for Inflammation Biology and Cancer Immunology, The Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, UK; Cancer Research UK King's Health Partner Cancer Centre, King's College London, London, UK; Université de Paris, Centre for Inflammation Research, CNRS ERL8252, INSERM1149 Paris, France.
| |
Collapse
|
21
|
Pol JG, Caudana P, Paillet J, Piaggio E, Kroemer G. Effects of interleukin-2 in immunostimulation and immunosuppression. J Exp Med 2020; 217:jem.20191247. [PMID: 31611250 PMCID: PMC7037245 DOI: 10.1084/jem.20191247] [Citation(s) in RCA: 91] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 08/29/2019] [Accepted: 09/23/2019] [Indexed: 12/19/2022] Open
Abstract
Distinctions in the nature and spatiotemporal expression of IL-2R subunits on conventional versus regulatory T cells are exploited to manipulate IL-2 immunomodulatory effects. Particularly, low-dose IL-2 and some recombinant derivatives are being evaluated to enhance/inhibit immune responses for therapeutic purposes. Historically, interleukin-2 (IL-2) was first described as an immunostimulatory factor that supports the expansion of activated effector T cells. A layer of sophistication arose when regulatory CD4+ T lymphocytes (Tregs) were shown to require IL-2 for their development, homeostasis, and immunosuppressive functions. Fundamental distinctions in the nature and spatiotemporal expression patterns of IL-2 receptor subunits on naive/memory/effector T cells versus Tregs are now being exploited to manipulate the immunomodulatory effects of IL-2 for therapeutic purposes. Although high-dose IL-2 administration has yielded discrete clinical responses, low-dose IL-2 as well as innovative strategies based on IL-2 derivatives, including “muteins,” immunocomplexes, and immunocytokines, are being explored to therapeutically enhance or inhibit the immune response.
Collapse
Affiliation(s)
- Jonathan G Pol
- Université de Paris, Paris, France.,Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U1138, Paris, France.,Sorbonne Université, Paris, France.,Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
| | - Pamela Caudana
- Institut Curie, Université de Recherche Paris Sciences & Lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM), U932, Paris, France
| | - Juliette Paillet
- Université de Paris, Paris, France.,Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U1138, Paris, France.,Sorbonne Université, Paris, France.,Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.,Université Paris-Sud/Paris XI, Faculté de Médecine, Kremlin-Bicêtre, France
| | - Eliane Piaggio
- Institut Curie, Université de Recherche Paris Sciences & Lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM), U932, Paris, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Guido Kroemer
- Université de Paris, Paris, France.,Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U1138, Paris, France.,Sorbonne Université, Paris, France.,Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.,Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance publique - Hôpitaux de Paris (AP-HP), Paris, France.,Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Suzhou, China.,Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
22
|
Núñez NG, Tosello Boari J, Ramos RN, Richer W, Cagnard N, Anderfuhren CD, Niborski LL, Bigot J, Meseure D, De La Rochere P, Milder M, Viel S, Loirat D, Pérol L, Vincent-Salomon A, Sastre-Garau X, Burkhard B, Sedlik C, Lantz O, Amigorena S, Piaggio E. Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nat Commun 2020; 11:3272. [PMID: 32601304 PMCID: PMC7324591 DOI: 10.1038/s41467-020-17046-2] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Accepted: 06/04/2020] [Indexed: 02/06/2023] Open
Abstract
Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates with poor prognosis and is associated with local immunosuppression, which can be partly mediated by regulatory T cells (Tregs). Here, we study Tregs from matched tumor-invaded and non-invaded TDLNs, and breast tumors. We observe that Treg frequencies increase with nodal invasion, and that Tregs express higher levels of co-inhibitory/stimulatory receptors than effector cells. Also, while Tregs show conserved suppressive function in TDLN and tumor, conventional T cells (Tconvs) in TDLNs proliferate and produce Th1-inflammatory cytokines, but are dysfunctional in the tumor. We describe a common transcriptomic signature shared by Tregs from tumors and nodes, including CD80, which is significantly associated with poor patient survival. TCR RNA-sequencing analysis indicates trafficking between TDLNs and tumors and ongoing Tconv/Treg conversion. Overall, TDLN Tregs are functional and express a distinct pattern of druggable co-receptors, highlighting their potential as targets for cancer immunotherapy.
Collapse
Affiliation(s)
- Nicolas Gonzalo Núñez
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
- Institute of Experimental Immunology, University of Zurich, Winterthurerstr. 190, CH-8057, Zurich, Switzerland
| | | | - Rodrigo Nalio Ramos
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
| | - Wilfrid Richer
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
| | - Nicolas Cagnard
- Paris-Descartes Bioinformatics Platform, 75015, Paris, France
| | - Cyrill Dimitri Anderfuhren
- Institute of Experimental Immunology, University of Zurich, Winterthurerstr. 190, CH-8057, Zurich, Switzerland
| | | | - Jeremy Bigot
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
| | - Didier Meseure
- Institut Curie, PSL Research University, Departement de Biologie des Tumeurs, F-75005, Paris, France
- Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris, F-75005, France
| | | | - Maud Milder
- Institut Curie, PSL Research University, Departement de Biologie des Tumeurs, F-75005, Paris, France
- Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris, F-75005, France
| | - Sophie Viel
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
| | - Delphine Loirat
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
- Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris, F-75005, France
- Institut Curie, PSL Research University, Departement d'Oncologie Medicale, F-75005, Paris, France
| | - Louis Pérol
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
| | - Anne Vincent-Salomon
- Institut Curie, PSL Research University, Departement de Biologie des Tumeurs, F-75005, Paris, France
- Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris, F-75005, France
| | - Xavier Sastre-Garau
- Institut Curie, PSL Research University, Departement de Biologie des Tumeurs, F-75005, Paris, France
- Institut de Cancerologie de Lorraine Department of Biopathology, 6, avenue de Bourgogne CS 30519, 54519, Vandoeuvre-lès-Nancy cedex, France
| | - Becher Burkhard
- Institute of Experimental Immunology, University of Zurich, Winterthurerstr. 190, CH-8057, Zurich, Switzerland
| | - Christine Sedlik
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
- Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris, F-75005, France
| | - Olivier Lantz
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
- Institut Curie, PSL Research University, Departement de Biologie des Tumeurs, F-75005, Paris, France
- Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris, F-75005, France
| | - Sebastian Amigorena
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France
- Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris, F-75005, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, F-75005, Paris, France.
- Centre d'Investigation Clinique Biotherapie CICBT 1428, Institut Curie, Paris, F-75005, France.
| |
Collapse
|
23
|
De Martino M, Tkach M, Mercogliano MF, Cenciarini ME, Chervo MF, Proietti CJ, Elizalde PV, Piaggio E, Schillaci R. Abstract B25: Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy. Cancer Immunol Res 2020. [DOI: 10.1158/2326-6074.tumimm18-b25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Stat3 is constitutively activated in diverse cancers and acts as a critical mediator of tumor immune evasion. Previously, we described in murine breast cancer (BC) models that blockade of Stat3 activation induces cellular senescence. Although senescent cells are growth arrested, they remain metabolically active and develop a senescence-associated secretory phenotype (SASP) that can have pro- as well as antitumorigenic effects. Our objectives were to characterize the composition and activity of the SASP induced by Stat3 blockade (SASP-Stat3) and to develop an immunotherapy (IT) based on this SASP. Here we report that Stat3 knockdown induced senescence and growth arrest only in tumor cells that exhibit constitutive activation of this oncogene (oncogene addiction), such as 4T1 BC and B16-OVA (herein “B16”) melanoma cells. Moreover, we observed that the SASP-Stat3 from 4T1 and B16 cells had several layers of antitumor effects. One of the effects relied on inhibition of tumor cell proliferation, migration and angiogenic activity. The other enhanced T-cell proliferation and activation in vitro. Furthermore, these effects were not observed with the conditioned medium (CM) from Stat3-blocked MCA cells, which are not Stat3 addicted. In order to translate these findings to a potential clinical application, we designed an immunization protocol based on the administration of irradiated wild-type cancer cells together with a depot of the SASP-Stat3. Therapeutic IT with SASP-Stat3 in mice bearing 4T1 or B16 tumors decreased tumor growth compared with control CM (CM-Control). In 4T1 tumors, we also observed a decrease in pulmonary metastasis vs. CM-Control. In addition, combination of the SASP-Stat3-based IT with an anti PD-1 antibody enhanced the antitumor activity against B16 tumor growth. We observed that this synergistic antitumor effect was the result of the involvement of different subsets of immune cells: SASP-Stat3-based IT activates CD4+ T cells and NK cells, while anti PD-1 therapy targets CD8+ T cells. Next, we studied the composition of the SASP-Stat3 through cytokine array and proteomic studies and disclosed several T cells and NK cells-attracting chemokines, IFNγ-induced cytokines and IFN-associated proteins (IP-10, RANTES, IL-15, MCP-1, ISG15 and IFI35). Taken together, these results demonstrate that Stat3 blockade in tumor cells that are addicted to this oncogene results in the induction of cellular senescence with the production of a SASP that has antitumoral and immune-stimulating activities. Cytokines and proteins from the SASP can be used to formulate an effective adjuvant to enhance the antitumor effect of anti-PD-1 antibodies.
Citation Format: Mara De Martino, Mercedes Tkach, María F. Mercogliano, Mauro E. Cenciarini, María F. Chervo, Cecilia J. Proietti, Patricia V. Elizalde, Eliane Piaggio, Roxana Schillaci. Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B25.
Collapse
Affiliation(s)
- Mara De Martino
- 1Institute of Biology and Experimental Medicine (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina,
| | - Mercedes Tkach
- 2Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - María F. Mercogliano
- 1Institute of Biology and Experimental Medicine (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina,
| | - Mauro E. Cenciarini
- 1Institute of Biology and Experimental Medicine (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina,
| | - María F. Chervo
- 1Institute of Biology and Experimental Medicine (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina,
| | - Cecilia J. Proietti
- 1Institute of Biology and Experimental Medicine (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina,
| | - Patricia V. Elizalde
- 1Institute of Biology and Experimental Medicine (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina,
| | - Eliane Piaggio
- 2Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Roxana Schillaci
- 1Institute of Biology and Experimental Medicine (IBYME-CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina,
| |
Collapse
|
24
|
Lynn GM, Sedlik C, Baharom F, Zhu Y, Ramirez-Valdez RA, Coble VL, Tobin K, Nichols SR, Itzkowitz Y, Zaidi N, Gammon JM, Blobel NJ, Denizeau J, de la Rochere P, Francica BJ, Decker B, Maciejewski M, Cheung J, Yamane H, Smelkinson MG, Francica JR, Laga R, Bernstock JD, Seymour LW, Drake CG, Jewell CM, Lantz O, Piaggio E, Ishizuka AS, Seder RA. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol 2020; 38:320-332. [PMID: 31932728 PMCID: PMC7065950 DOI: 10.1038/s41587-019-0390-x] [Citation(s) in RCA: 177] [Impact Index Per Article: 44.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Accepted: 12/10/2019] [Indexed: 12/16/2022]
Abstract
Personalized cancer vaccines targeting patient-specific neoantigens are a promising cancer treatment modality; however, neoantigen physicochemical variability can present challenges to manufacturing personalized cancer vaccines in an optimal format for inducing anticancer T cells. Here, we developed a vaccine platform (SNP-7/8a) based on charge-modified peptide-TLR-7/8a conjugates that are chemically programmed to self-assemble into nanoparticles of uniform size (~20 nm) irrespective of the peptide antigen composition. This approach provided precise loading of diverse peptide neoantigens linked to TLR-7/8a (adjuvant) in nanoparticles, which increased uptake by and activation of antigen-presenting cells that promote T-cell immunity. Vaccination of mice with SNP-7/8a using predicted neoantigens (n = 179) from three tumor models induced CD8 T cells against ~50% of neoantigens with high predicted MHC-I binding affinity and led to enhanced tumor clearance. SNP-7/8a delivering in silico-designed mock neoantigens also induced CD8 T cells in nonhuman primates. Altogether, SNP-7/8a is a generalizable approach for codelivering peptide antigens and adjuvants in nanoparticles for inducing anticancer T-cell immunity.
Collapse
Affiliation(s)
- Geoffrey M Lynn
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
- Avidea Technologies, Inc, Baltimore, MD, USA.
| | - Christine Sedlik
- Institut Curie, PSL Research University, Paris, France
- Centre d'Investigation Clinique Biothérapie, Institut Curie, Paris, France
| | - Faezzah Baharom
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Yaling Zhu
- Avidea Technologies, Inc, Baltimore, MD, USA
| | - Ramiro A Ramirez-Valdez
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | | | - Kennedy Tobin
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | | | | | - Neeha Zaidi
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Joshua M Gammon
- Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA
| | - Nicolas J Blobel
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Jordan Denizeau
- Institut Curie, PSL Research University, Paris, France
- Centre d'Investigation Clinique Biothérapie, Institut Curie, Paris, France
| | - Philippe de la Rochere
- Institut Curie, PSL Research University, Paris, France
- Centre d'Investigation Clinique Biothérapie, Institut Curie, Paris, France
| | - Brian J Francica
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
- Tempest Therapeutics, San Francisco, CA, USA
| | | | | | - Justin Cheung
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Hidehiro Yamane
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Margery G Smelkinson
- Biological Imaging Section, Research Technologies Branch, NIAID, NIH, Bethesda, MD, USA
| | - Joseph R Francica
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Richard Laga
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Joshua D Bernstock
- Avidea Technologies, Inc, Baltimore, MD, USA
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard University, Boston, MA, USA
| | | | - Charles G Drake
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
| | - Christopher M Jewell
- Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA
| | - Olivier Lantz
- Institut Curie, PSL Research University, Paris, France
- Centre d'Investigation Clinique Biothérapie, Institut Curie, Paris, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, Paris, France
- Centre d'Investigation Clinique Biothérapie, Institut Curie, Paris, France
| | - Andrew S Ishizuka
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
- Avidea Technologies, Inc, Baltimore, MD, USA
| | - Robert A Seder
- Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
| |
Collapse
|
25
|
Ramos RN, Rodriguez C, Hubert M, Ardin M, Treilleux I, Ries CH, Lavergne E, Chabaud S, Colombe A, Trédan O, Guedes HG, Laginha F, Richer W, Piaggio E, Barbuto JAM, Caux C, Ménétrier-Caux C, Bendriss-Vermare N. CD163 + tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clin Transl Immunology 2020; 9:e1108. [PMID: 32082570 PMCID: PMC7017151 DOI: 10.1002/cti2.1108] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 12/19/2019] [Accepted: 01/13/2020] [Indexed: 12/24/2022] Open
Abstract
Objectives The accumulation of tumor‐associated macrophages (TAMs) is correlated with poor clinical outcome, but the mechanisms governing their differentiation from circulating monocytes remain unclear in humans. Methods Using multicolor flow cytometry, we evaluated TAMs phenotype in 93 breast cancer (BC) patients. Furthermore, monocytes from healthy donors were cultured in the presence of supernatants from dilacerated primary tumors to investigate their differentiation into macrophages (MΦ) in vitro. Additionally, we used transcriptomic analysis to evaluate BC patients’ blood monocytes profiles. Results We observed that high intra‐tumor CD163‐expressing TAM density is predictive of reduced survival in BC patients. In vitro, M‐CSF, TGF‐β and VEGF from primary tumor supernatants skewed the differentiation of healthy donor blood monocytes towards CD163highCD86lowIL‐10high M2‐like MΦ that strongly suppressed CD4+ T‐cell expansion via PD‐L1 and IL‐10. In addition, blood monocytes from about 40% of BC patients displayed an altered response to in vitro stimulation, being refractory to type‐1 MΦ (M1‐MΦ) differentiation and secreting higher amounts of immunosuppressive, metastatic‐related and angiogenic cytokines. Aside from showing that monocyte transcriptome is significantly altered by the presence of BC, we also demonstrated an overall metabolic de‐activation in refractory monocytes of BC patients. In contrast, monocytes from sensitive BC patients undergoing normal M1‐MΦ differentiation showed up‐regulation of IFN‐response genes and had no signs of metabolic alteration. Conclusion Altogether, our results suggest that systemic factors skew BC patient blood monocytes towards a pro‐metastatic profile, resulting in the accumulation of further polarised CD163high TAMs resembling type‐2 MΦ (M2‐MΦ) in the local BC microenvironment. These data indicate that monitoring circulating monocytes in BC patients may provide an indication of early systemic alterations induced by cancer and, thus, be instrumental in the development of improved personalised immunotherapeutic interventions.
Collapse
Affiliation(s)
- Rodrigo Nalio Ramos
- INSERM U1052 CNRS 5286 Centre Léon Bérard Centre de Recherche en Cancérologie de Lyon Univ Lyon Université Claude Bernard Lyon 1 Lyon France.,Department of Immunology Institute of Biomedical Sciences - University of São Paulo São Paulo Brazil
| | - Céline Rodriguez
- INSERM U1052 CNRS 5286 Centre Léon Bérard Centre de Recherche en Cancérologie de Lyon Univ Lyon Université Claude Bernard Lyon 1 Lyon France
| | - Margaux Hubert
- INSERM U1052 CNRS 5286 Centre Léon Bérard Centre de Recherche en Cancérologie de Lyon Univ Lyon Université Claude Bernard Lyon 1 Lyon France
| | - Maude Ardin
- INSERM U1052 CNRS 5286 Centre Léon Bérard Centre de Recherche en Cancérologie de Lyon Univ Lyon Université Claude Bernard Lyon 1 Lyon France
| | | | - Carola H Ries
- Roche Pharmaceutical Research and Early Development Roche Innovation Center Munich Penzberg Germany
| | | | | | | | | | | | | | - Wilfrid Richer
- Institut Curie PSL Research University Paris France.,INSERM U932 Paris France
| | - Eliane Piaggio
- Institut Curie PSL Research University Paris France.,INSERM U932 Paris France
| | - José Alexandre M Barbuto
- Department of Immunology Institute of Biomedical Sciences - University of São Paulo São Paulo Brazil
| | - Christophe Caux
- INSERM U1052 CNRS 5286 Centre Léon Bérard Centre de Recherche en Cancérologie de Lyon Univ Lyon Université Claude Bernard Lyon 1 Lyon France
| | - Christine Ménétrier-Caux
- INSERM U1052 CNRS 5286 Centre Léon Bérard Centre de Recherche en Cancérologie de Lyon Univ Lyon Université Claude Bernard Lyon 1 Lyon France
| | - Nathalie Bendriss-Vermare
- INSERM U1052 CNRS 5286 Centre Léon Bérard Centre de Recherche en Cancérologie de Lyon Univ Lyon Université Claude Bernard Lyon 1 Lyon France
| |
Collapse
|
26
|
De Martino M, Tkach M, Bruni S, Rocha D, Mercogliano MF, Cenciarini ME, Chervo MF, Proietti CJ, Dingli F, Loew D, Fernández EA, Elizalde PV, Piaggio E, Schillaci R. Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy. Oncoimmunology 2020; 9:1715767. [PMID: 32064174 PMCID: PMC6996562 DOI: 10.1080/2162402x.2020.1715767] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Revised: 01/09/2020] [Accepted: 01/10/2020] [Indexed: 12/19/2022] Open
Abstract
Stat3 is constitutively activated in several tumor types and plays an essential role in maintaining their malignant phenotype and immunosupression. To take advantage of the promising antitumor activity of Stat3 targeting, it is vital to understand the mechanism by which Stat3 regulates both cell autonomous and non-autonomous processes. Here, we demonstrated that turning off Stat3 constitutive activation in different cancer cell types induces senescence, thus revealing their Stat3 addiction. Taking advantage of the senescence-associated secretory phenotype (SASP) induced by Stat3 silencing (SASP-siStat3), we designed an immunotherapy. The administration of SASP-siStat3 immunotherapy induced a strong inhibition of triple-negative breast cancer and melanoma growth associated with activation of CD4 + T and NK cells. Combining this immunotherapy with anti-PD-1 antibody resulted in survival improvement in mice bearing melanoma. The characterization of the SASP components revealed that type I IFN-related mediators, triggered by the activation of the cyclic GMP-AMP synthase DNA sensing pathway, are important for its immunosurveillance activity. Overall, our findings provided evidence that administration of SASP-siStat3 or low dose of Stat3-blocking agents would benefit patients with Stat3-addicted tumors to unleash an antitumor immune response and to improve the effectiveness of immune checkpoint inhibitors.
Collapse
Affiliation(s)
- Mara De Martino
- Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología Y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
| | - Mercedes Tkach
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Sofía Bruni
- Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología Y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
| | - Darío Rocha
- Facultad de Ciencias Exactas, Físicas Y Naturales, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - María F Mercogliano
- Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología Y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
| | - Mauro E Cenciarini
- Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología Y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
| | - María F Chervo
- Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología Y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
| | - Cecilia J Proietti
- Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología Y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
| | - Florent Dingli
- Institut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, Paris, France
| | - Damarys Loew
- Institut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, Paris, France
| | - Elmer A Fernández
- Facultad de Ciencias Exactas, Físicas Y Naturales, Universidad Nacional de Córdoba, Córdoba, Argentina.,Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas (CIDIE), Universidad Católica De Córdoba, Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET), Córdoba, Argentina
| | - Patricia V Elizalde
- Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología Y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Roxana Schillaci
- Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología Y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
| |
Collapse
|
27
|
Leruste A, Tosello J, Ramos RN, Tauziède-Espariat A, Brohard S, Han ZY, Beccaria K, Andrianteranagna M, Caudana P, Nikolic J, Chauvin C, Niborski LL, Manriquez V, Richer W, Masliah-Planchon J, Grossetête-Lalami S, Bohec M, Lameiras S, Baulande S, Pouponnot C, Coulomb A, Galmiche L, Surdez D, Servant N, Helft J, Sedlik C, Puget S, Benaroch P, Delattre O, Waterfall JJ, Piaggio E, Bourdeaut F. Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. Cancer Cell 2019; 36:597-612.e8. [PMID: 31708437 DOI: 10.1016/j.ccell.2019.10.008] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 08/06/2019] [Accepted: 10/22/2019] [Indexed: 01/01/2023]
Abstract
Rhabdoid tumors (RTs) are genomically simple pediatric cancers driven by the biallelic inactivation of SMARCB1, leading to SWI/SNF chromatin remodeler complex deficiency. Comprehensive evaluation of the immune infiltrates of human and mice RTs, including immunohistochemistry, bulk RNA sequencing and DNA methylation profiling studies showed a high rate of tumors infiltrated by T and myeloid cells. Single-cell RNA (scRNA) and T cell receptor sequencing highlighted the heterogeneity of these cells and revealed therapeutically targetable exhausted effector and clonally expanded tissue resident memory CD8+ T subpopulations, likely representing tumor-specific cells. Checkpoint blockade therapy in an experimental RT model induced the regression of established tumors and durable immune responses. Finally, we show that one mechanism mediating RTs immunogenicity involves SMARCB1-dependent re-expression of endogenous retroviruses and interferon-signaling activation.
Collapse
Affiliation(s)
- Amaury Leruste
- PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France
| | - Jimena Tosello
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Rodrigo Nalio Ramos
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | | | - Solène Brohard
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France
| | - Zhi-Yan Han
- PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France
| | - Kevin Beccaria
- AP-HP, Necker Hospital, Department of Neurosurgery, Paris, France
| | - Mamy Andrianteranagna
- PSL Research University, Institut Curie Research Center, INSERM U900, Paris, France; MINES ParisTech, PSL Research University, CBIO-Centre for Computational Biology, Paris, France
| | - Pamela Caudana
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Jovan Nikolic
- PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Céline Chauvin
- PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France
| | - Leticia Laura Niborski
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Valeria Manriquez
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Wilfrid Richer
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Julien Masliah-Planchon
- PSL Research University, Institut Curie Hospital, Laboratory of Somatic Genetics, Paris, France
| | - Sandrine Grossetête-Lalami
- PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France
| | - Mylene Bohec
- PSL Research University, Institut Curie Genomics of Excellence (ICGex) Platform, Paris, France
| | - Sonia Lameiras
- PSL Research University, Institut Curie Genomics of Excellence (ICGex) Platform, Paris, France
| | - Sylvain Baulande
- PSL Research University, Institut Curie Genomics of Excellence (ICGex) Platform, Paris, France
| | - Celio Pouponnot
- PSL Research University, Institut Curie Research Center, CNRS UMR 3347, INSERM U1021, Orsay, France
| | - Aurore Coulomb
- AP-HP, Armand Trousseau Hospital, Department of Pathology, Paris, France
| | - Louise Galmiche
- AP-HP, Necker Hospital, Department of Pathology, Paris, France
| | - Didier Surdez
- PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France
| | - Nicolas Servant
- PSL Research University, Institut Curie Research Center, INSERM U900, Paris, France; MINES ParisTech, PSL Research University, CBIO-Centre for Computational Biology, Paris, France
| | - Julie Helft
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Christine Sedlik
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Stéphanie Puget
- AP-HP, Necker Hospital, Department of Neurosurgery, Paris, France
| | - Philippe Benaroch
- PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France
| | - Olivier Delattre
- PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France
| | - Joshua J Waterfall
- PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France.
| | - Eliane Piaggio
- PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France.
| | - Franck Bourdeaut
- PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; PSL Research University, Institut Curie Research Center, Translational Research Department, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France.
| |
Collapse
|
28
|
Merlotti A, Malizia AL, Michea P, Bonte PE, Goudot C, Carregal MS, Nuñez N, Sedlik C, Ceballos A, Soumelis V, Amigorena S, Geffner J, Piaggio E, Sabatte J. Aberrant fucosylation enables breast cancer clusterin to interact with dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN). Oncoimmunology 2019; 8:e1629257. [PMID: 31428526 PMCID: PMC6685524 DOI: 10.1080/2162402x.2019.1629257] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 05/30/2019] [Accepted: 06/01/2019] [Indexed: 01/26/2023] Open
Abstract
Clusterin is a glycoprotein able to mediate different physiological functions such as control of complement activation, promotion of unfolded protein clearance and modulation of cell survival. Clusterin is overexpressed in many types of cancers and a large body of evidence suggests that it promotes carcinogenesis and tumor progression. We have previously described a novel clusterin glycoform present in human semen, but not in serum, highly enriched in terminal fucose motifs. Here we show that human luminal breast cancer (LBC) clusterin also bears terminal fucosylated glycans, conferring clusterin the ability to interact with DC-SIGN, a C-type lectin receptor expressed by myeloid cells. This clusterin glycosylation pattern was absent or diminished in non-involved juxtatumoral tissue, suggesting that fucosylated clusterin might represent a cancer associated glycoform. We also found that DC-SIGN is expressed by luminal breast cancer intratumoral macrophages. Moreover, experiments performed in vitro using semen fucosylated clusterin and monocyte derived macrophages showed that the interaction of semen clusterin with DC-SIGN promoted a proangiogenic profile, characterized by a high production of VEGF, IL-8 and TNF-α. Our results reveal an unexpected complexity on the structure and function of secretory clusterin produced by tumors and suggest that fucosylated clusterin produced by luminal breast cancer cells might play a role in tumor progression by promoting the release of pro-angiogenic factors by intratumoral macrophages.
Collapse
Affiliation(s)
- Antonela Merlotti
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.,Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Alvaro López Malizia
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Paula Michea
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | | | - Christel Goudot
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - María Sol Carregal
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Nicolás Nuñez
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Christine Sedlik
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Ana Ceballos
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Vassili Soumelis
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | | | - Jorge Geffner
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Juan Sabatte
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
29
|
Burlion A, Ramos RN, Kc P, Sendeyo K, Corneau A, Ménétrier-Caux C, Piaggio E, Olive D, Caux C, Marodon G. A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system. Oncoimmunology 2019; 8:1596005. [PMID: 31143518 PMCID: PMC6527285 DOI: 10.1080/2162402x.2019.1596005] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Revised: 03/01/2019] [Accepted: 03/05/2019] [Indexed: 02/08/2023] Open
Abstract
Mice reconstituted with a human immune system and bearing human tumors represent a promising model for developing novel cancer immunotherapies. Here, we used mass cytometry and multi-parametric flow cytometry to characterize human leukocytes infiltrating a human breast cancer tumor model in immunocompromised NOD.SCID.γc-null mice reconstituted with a human immune system and compared it to samples of breast cancer patients. We observed highly activated human CD4+ and CD8+ T cells in the tumor, as well as minor subsets of innate immune cells in both settings. We also report that ICOS+ CD4+ regulatory T cells (Treg) were enriched in the tumor relative to the periphery in humanized mice and patients, providing a target to affect Treg and tumor growth. Indeed, administration of a neutralizing mAb to human ICOS reduced Treg proportions and numbers and improved CD4 + T cell proliferation in humanized mice. Moreover, a combination of the anti-ICOS mAb with cyclophosphamide reduced tumor growth, and that was associated with an improved CD8 to Treg ratio. Depletion of human CD8+ T cells or of murine myeloid cells marginally affected the effect of the combination therapy. Altogether, our results indicate that a combination of anti-ICOS mAb and chemotherapy controls tumor growth in humanized mice, opening new perspectives for the treatment of breast cancer. One sentence summary: Targeting ICOS in combination with chemotherapy is a promising strategy to improve tumor immunity in humans.
Collapse
Affiliation(s)
- Aude Burlion
- CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Sorbonne Université, Paris, France
| | - Rodrigo N Ramos
- INSERM U932, SiRIC Translational Immunotherapy Team, Institut Curie, Paris Sciences et Lettres Research University, Paris, France
| | - Pukar Kc
- CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Sorbonne Université, Paris, France
| | - Kélhia Sendeyo
- CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Sorbonne Université, Paris, France
| | | | - Christine Ménétrier-Caux
- INSERM 1052, CNRS 5286, Department of Translational Research and Innovation, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, CRCL, Université Claude Bernard Lyon 1, Lyon, France
| | - Eliane Piaggio
- INSERM U932, SiRIC Translational Immunotherapy Team, Institut Curie, Paris Sciences et Lettres Research University, Paris, France
| | - Daniel Olive
- INSERM U1068, CNRS, Institut Paoli - Calmettes, Centre de recherche en Cancérologie de Marseille, CRCM, Aix Marseille Université, Marseille, France
| | - Christophe Caux
- INSERM 1052, CNRS 5286, Department of Translational Research and Innovation, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, CRCL, Université Claude Bernard Lyon 1, Lyon, France
| | - Gilles Marodon
- CNRS, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Sorbonne Université, Paris, France
| |
Collapse
|
30
|
Roselli E, Araya P, Núñez NG, Gatti G, Graziano F, Sedlik C, Benaroch P, Piaggio E, Maccioni M. TLR3 Activation of Intratumoral CD103 + Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity. Front Immunol 2019; 10:503. [PMID: 30949170 PMCID: PMC6435583 DOI: 10.3389/fimmu.2019.00503] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Accepted: 02/25/2019] [Indexed: 12/28/2022] Open
Abstract
An important challenge in cancer immunotherapy is to expand the number of patients that benefit from immune checkpoint inhibitors (CI), a fact that has been related to the pre-existence of an efficient anti-tumor immune response. Different strategies are being proposed to promote tumor immunity and to be used in combined therapies with CI. Recently, we reported that intratumoral administration of naked poly A:U, a dsRNA mimetic empirically used in early clinical trials with some success, delays tumor growth and prolongs mice survival in several murine cancer models. Here, we show that CD103+ cDC1 and, to a much lesser extent CD11b+ cDC2, are the only populations expressing TLR3 at the tumor site, and consequently could be potential targets of poly A:U. Upon poly A:U administration these cells become activated and elicit profound changes in the composition of the tumor immune infiltrate, switching the immune suppressive tumor environment to anti-tumor immunity. The sole administration of naked poly A:U promotes striking changes within the lymphoid compartment, with all the anti-tumoral parameters being enhanced: a higher frequency of CD8+ Granzyme B+ T cells, (lower Treg/CD8+ ratio) and an important expansion of tumor-antigen specific CD8+ T cells. Also, PD1/PDL1 showed an increased expression indicating that neutralization of this axis could be exploited in combination with poly A:U. Our results shed new light to promote further assays in this dsRNA mimetic to the clinical field.
Collapse
Affiliation(s)
- Emiliano Roselli
- Department of Clinical Biochemistry, Faculty of Chemical Sciences, Center for Research in Clinical Biochemistry and Immunology, National University of Cordoba, Cordoba, Argentina
| | - Paula Araya
- Department of Clinical Biochemistry, Faculty of Chemical Sciences, Center for Research in Clinical Biochemistry and Immunology, National University of Cordoba, Cordoba, Argentina
| | | | - Gerardo Gatti
- Fundación para el Progreso de la Medicina, Laboratorio de Investigación en Cáncer, Cordoba, Argentina
| | | | | | | | | | - Mariana Maccioni
- Department of Clinical Biochemistry, Faculty of Chemical Sciences, Center for Research in Clinical Biochemistry and Immunology, National University of Cordoba, Cordoba, Argentina
| |
Collapse
|
31
|
Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncoimmunology 2019; 8:e1581556. [PMID: 31069145 PMCID: PMC6492984 DOI: 10.1080/2162402x.2019.1581556] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 01/18/2019] [Accepted: 02/06/2019] [Indexed: 12/14/2022] Open
Abstract
Although immune checkpoint inhibitors have shown improvement in survival in comparison to chemotherapy in urothelial bladder cancer, many patients still fail to respond to these treatments and actual efforts are made to identify predictive factors of response to immunotherapy. Understanding the tumor-intrinsic molecular basis, like oncogenic pathways conditioning the presence or absence of tumor-infiltrating T cells (TILs), should provide a new rationale for improved anti-tumor immune therapies. In this study, we found that urothelial bladder cancer from human samples bearing PIK3CA gene mutations was significantly associated with lower expression of a defined immune gene signature, compared to unmutated ones. We identified a reduced 10-gene immune gene signature that discriminates muscle-invasive bladder cancer (MIBC) samples according to immune infiltration and PIK3CA mutation. Using a humanized mouse model, we observed that BKM120, a pan-PI3K inhibitor, significantly inhibited the growth of a human bladder cancer cell line bearing a PIK3CA mutation, associated to increased immune cell infiltration (hCD45+). Using qRT-PCR, we also found an increase in the expression of chemokines and immune genes in PIK3CA-mutated tumors from mice treated with BKM120, reflecting an active immune infiltrate in comparison to untreated ones. Moreover, the addition of BKM120 rendered PIK3CA-mutated tumors sensitive to PD-1 blockade. Our results provide a relevant rationale for combination strategies of PI3K inhibitors with immune checkpoint inhibitors to overcome resistance to immune checkpoint inhibitors.
Collapse
Affiliation(s)
- Edith Borcoman
- Department of Medical Oncology, Institut Curie, Paris, France.,Institut Curie, PSL Research University, INSERM U932, Paris, France
| | | | - Wilfrid Richer
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Sophie Vacher
- Department of Genetics, Institut Curie, Paris, France
| | | | | | - Nanour Sirab
- Institut Curie, PSL Research University, CNRS UMR 144, Paris, France
| | - Francois Radvanyi
- Institut Curie, PSL Research University, CNRS UMR 144, Paris, France
| | - Yves Allory
- Institut Curie, PSL Research University, CNRS UMR 144, Paris, France.,Department of diagnostic and theranostic medicine, Institut Curie, Saint-Cloud, France
| | - Géraldine Pignot
- Department of Urology, Institut Paoli-Calmettes, Marseille, France
| | | | - Diane Damotte
- Department of Pathology, Hôpital Cochin, Paris, France
| | - Didier Meseure
- Department of diagnostic and theranostic medicine, Institut Curie, Paris, France
| | - Christine Sedlik
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Ivan Bieche
- Department of Genetics, Institut Curie, Paris, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris, France
| |
Collapse
|
32
|
Caudana P, Núñez NG, De La Rochere P, Pinto A, Denizeau J, Alonso R, Niborski LL, Lantz O, Sedlik C, Piaggio E. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation. Cancer Immunol Res 2019; 7:443-457. [PMID: 30651291 DOI: 10.1158/2326-6066.cir-18-0697] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Revised: 12/21/2018] [Accepted: 01/11/2019] [Indexed: 11/16/2022]
Abstract
High-dose IL2 immunotherapy can induce long-lasting cancer regression but is toxic and insufficiently efficacious. Improvements are obtained with IL2/anti-IL2 complexes (IL2Cx), which redirect IL2 action to CD8+ T and natural killer (NK) cells. Here, we evaluated the efficacy of combining IL2Cx with blockade of inhibitory immune pathways. In an autochthonous lung adenocarcinoma model, we show that the IL2Cx/anti-PD-1 combination increases CD8+ T-cell infiltration of the lung and controls tumor growth. In the B16-OVA model, which is resistant to checkpoint inhibition, combination of IL2Cx with PD-1 or CTLA-4 pathway blockade reverses that resistance. Both combinations work by reinvigorating exhausted intratumoral CD8+ T cells and by increasing the breadth of tumor-specific T-cell responses. However, only the IL2Cx/anti-CTLA-4 combination is able to rescue NK cell antitumor function by modulating intratumoral regulatory T cells. Overall, association of IL2Cx with PD-1 or CTLA-4 pathway blockade acts by different cellular mechanisms, paving the way for the rational design of combinatorial antitumor therapies.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal/therapeutic use
- Antigen-Antibody Complex/therapeutic use
- CD8-Positive T-Lymphocytes/immunology
- CTLA-4 Antigen/immunology
- Cell Line, Tumor
- Disease Models, Animal
- Drug Resistance, Neoplasm/drug effects
- Female
- Immunotherapy
- Interleukin-2/immunology
- Killer Cells, Natural/immunology
- Lymphocytes, Tumor-Infiltrating/immunology
- Mice
- Mice, Inbred C57BL
- Mice, Mutant Strains
- Neoplasms, Experimental/immunology
- Neoplasms, Experimental/therapy
- Programmed Cell Death 1 Receptor/immunology
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Regulatory/immunology
- Tumor Microenvironment/drug effects
- Tumor Microenvironment/immunology
Collapse
Affiliation(s)
- Pamela Caudana
- Institut Curie, PSL Research University, INSERM U932, TransImm Team, Paris, France
| | | | | | - Anaïs Pinto
- Institut Curie, PSL Research University, INSERM U932, TransImm Team, Paris, France
| | - Jordan Denizeau
- Institut Curie, PSL Research University, INSERM U932, TransImm Team, Paris, France
| | - Ruby Alonso
- Institut Curie, PSL Research University, INSERM U932, TransImm Team, Paris, France
| | | | - Olivier Lantz
- Institut Curie, PSL Research University, INSERM U932, TransImm Team, Paris, France
- Institut Curie, PSL Research University, Clinical Immunology Laboratory, Paris, France
- Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Christine Sedlik
- Institut Curie, PSL Research University, INSERM U932, TransImm Team, Paris, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, TransImm Team, Paris, France.
- Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| |
Collapse
|
33
|
Frazao A, Messaoudene M, Nunez N, Dulphy N, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A. CD16 +NKG2A high Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes. Cancer Immunol Res 2018; 7:208-218. [PMID: 30514793 DOI: 10.1158/2326-6066.cir-18-0085] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Revised: 07/03/2018] [Accepted: 11/27/2018] [Indexed: 11/16/2022]
Abstract
Tumor-draining lymph nodes (TD-LNs) are the first site of metastasis of breast cancer. Natural killer (NK) cells that infiltrate TD-LNs [including noninvaded (NI) or metastatic (M)-LNs from breast cancer patients] and NK cells from healthy donor (HD)-LNs were characterized, and their phenotype analyzed by flow cytometry. Low percentages of tumor cells invaded M-LNs, and these cells expressed ULBP2 and HLA class I molecules. Although NK cells from paired NI and M-LNs were similar, they expressed different markers compared with HD-LN NK cells. Compared with HD-LNs, TD-LN NK cells expressed activating DNAM-1, NKG2C and inhibitory NKG2A receptors, and exhibited elevated CXCR3 expression. CD16, NKG2A, and NKp46 expression were shown to be increased in stage IIIA breast cancer patients. TD-LNs contained a large proportion of activated CD56brightCD16+ NK cells with high expression of NKG2A. We also showed that a subset of LN NK cells expressed PD-1, expression of which was correlated with NKp30 and NKG2C expression. LN NK cell activation status was evaluated by degranulation potential and lytic capacity toward breast cancer cells. NK cells from TD-LNs degranulated after coculture with breast cancer cell lines. Cytokine-activated TD-LN NK cells exerted greater lysis of breast cancer cell lines than HD-LN NK cells and preferentially lysed the HLA class Ilow MCF-7 breast cancer cell line. TD-LNs from breast cancer patients, thus, contained activated lytic NK cells. The expression of inhibitory receptor NKG2A and checkpoint PD-1 by NK cells infiltrating breast cancer-draining LNs supports their potential as targets for immunotherapies using anti-NKG2A and/or anti-PD-1.
Collapse
Affiliation(s)
- Alexandra Frazao
- INSERM U1160, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris, France.,Univ. Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Paris, France
| | - Meriem Messaoudene
- INSERM U1160, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris, France.,Gustave Roussy Cancer Campus (GRCC), Villejuif, France
| | - Nicolas Nunez
- Institut Curie, PSL Research University, INSERM U932, Paris, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Nicolas Dulphy
- INSERM U1160, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris, France.,Univ. Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France
| | - France Roussin
- Service d'Anesthésie-Réanimation, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Christine Sedlik
- Institut Curie, PSL Research University, INSERM U932, Paris, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Laurence Zitvogel
- Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Villejuif, France.,Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.,Univ. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Antoine Toubert
- INSERM U1160, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris, France.,Univ. Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France
| | - Anne Caignard
- INSERM U1160, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris, France.
| |
Collapse
|
34
|
Tosello Boari J, Araujo Furlan CL, Fiocca Vernengo F, Rodriguez C, Ramello MC, Amezcua Vesely MC, Gorosito Serrán M, Nuñez NG, Richer W, Piaggio E, Montes CL, Gruppi A, Acosta Rodríguez EV. IL-17RA-Signaling Modulates CD8+ T Cell Survival and Exhaustion During Trypanosoma cruzi Infection. Front Immunol 2018; 9:2347. [PMID: 30364284 PMCID: PMC6193063 DOI: 10.3389/fimmu.2018.02347] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Accepted: 09/21/2018] [Indexed: 12/12/2022] Open
Abstract
The IL-17 family contributes to host defense against many intracellular pathogens by mechanisms that are not fully understood. CD8+ T lymphocytes are key elements against intracellular microbes, and their survival and ability to mount cytotoxic responses are orchestrated by several cytokines. Here, we demonstrated that IL-17RA-signaling cytokines sustain pathogen-specific CD8+ T cell immunity. The absence of IL-17RA and IL-17A/F during Trypanosoma cruzi infection resulted in increased tissue parasitism and reduced frequency of parasite-specific CD8+ T cells. Impaired IL-17RA-signaling in vivo increased apoptosis of parasite-specific CD8+ T cells, while in vitro recombinant IL-17 down-regulated the pro-apoptotic protein BAD and promoted the survival of activated CD8+ T cells. Phenotypic, functional, and transcriptomic profiling showed that T. cruzi-specific CD8+ T cells derived from IL-17RA-deficient mice presented features of cell dysfunction. PD-L1 blockade partially restored the magnitude of CD8+ T cell responses and parasite control in these mice. Adoptive transfer experiments established that IL-17RA-signaling is intrinsically required for the proper maintenance of functional effector CD8+ T cells. Altogether, our results identify IL-17RA and IL-17A as critical factors for sustaining CD8+ T cell immunity to T. cruzi.
Collapse
Affiliation(s)
- Jimena Tosello Boari
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Cintia L. Araujo Furlan
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Facundo Fiocca Vernengo
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Constanza Rodriguez
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - María C. Ramello
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - María C. Amezcua Vesely
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Melisa Gorosito Serrán
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Nicolás G. Nuñez
- SiRIC TransImm “Translational Immunotherapy Team,” Translational Research Department, Research Center, PSL Research University, INSERM U932, Institut Curie, Paris, France
- Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Wilfrid Richer
- SiRIC TransImm “Translational Immunotherapy Team,” Translational Research Department, Research Center, PSL Research University, INSERM U932, Institut Curie, Paris, France
- Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Eliane Piaggio
- SiRIC TransImm “Translational Immunotherapy Team,” Translational Research Department, Research Center, PSL Research University, INSERM U932, Institut Curie, Paris, France
- Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Carolina L. Montes
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Adriana Gruppi
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| | - Eva V. Acosta Rodríguez
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología, CONICET, Córdoba, Argentina
| |
Collapse
|
35
|
Canale FP, Ramello MC, Núñez N, Bossio SN, Piaggio E, Gruppi A, Rodríguez EVA, Montes CL. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells—Response. Cancer Res 2018; 78:5175. [DOI: 10.1158/0008-5472.can-18-0950] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/22/2018] [Accepted: 06/18/2018] [Indexed: 11/16/2022]
|
36
|
Montaudon E, Vacher S, Richer W, Dahmani A, Guibaudet C, Déas O, Cairo S, Plater LD, Dubois M, Némati F, Sedlik C, Judde JG, Girard N, Bieche I, Piaggio E, Decaudin D. Abstract 1718: Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-1718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The blockade of immune checkpoints with antibodies directed against CTLA-4, PD-1 and PD-L1 molecules, is now entering in the current management of non-small cell lung cancer (NSCLC) patients; those tumors are heterogeneous regarding driver oncogenes, which predict the efficacy of targeted therapies (TT). In this context, our study aimed to define the relationship between conventional TT used in NSCLC and the dynamic expression of immune genes.
Experimental procedure: Eight different NSCLC Patient-Derived Xenografts (PDXs) with defined mutations, were grafted in immunodeficient mice which were then treated by various TT (Table). About 3 tumors per group were collected at the end of the in vivo experiments. The expression of human and mouse genes, using species-specific primers was determined by qPCR and normalized to the expression of the human or mouse Total Binding Protein gene. Basal gene expression, predictive markers of response and resistance to tested therapies, as well as pharmacodynamics (PD) markers were analyzed.
Results: Basal immune gene expression analysis revealed various immune profiles in this panel of NSCLC PDXs, with clustering of both models and genes. Predictive and pharmacodynamics markers underlined the impact of human HLA class I and II gene expression in the response to erlotinib and everolimus (HLA-A, HLA-DRA, and HLA-DRB); of B7-H3 (CD276), PDL1 (CD274) and Tigit (PVRIG) in the response to erlotinib; and of TNFSF7 (CD70) and TNFSF9 in the response to BKM120. PD markers showed that PDL1, B7-H3, and Tigit expression was highly impacted by everolimus, erlotinib, and BKM120 treatments, respectively. Complete gene expression results can be presented at the meeting.
Conclusions: Using NSCLC PDXs, we have identified specific tumor immune profiles and a set of genes involved in the response to TT. Moreover, PD analysis of immune markers reveals potential combinations of TT with immune checkpoints blockade that may have important translational value.
NSCLC PDXsLCF4LCF9LCF12LCF15LCF25LCF29ML1ML5HistologyAdenocarcinomaXXXXXXXLarge cellsXMUTATIONSEGFRXXKRASXXPi3KCAXXXTREATMENTS (Targets)Cetuximab (1)EGFRXXXXErlotinib (2)EGFRXXXXAfatinib (3)EGFR/HER2XXXXBKM120 (4)Pi3KXXXXXXXXEverolimus (5)mTORC1XXXXSelumetinib (6)MEK1/2XXXXXXXX1 + 2/XXXX1 + 3/XXXX1 + 4/X2 + 4/X3 + 4/X5 + 6/XXXX
Citation Format: Elodie Montaudon, Sophie Vacher, Wilfrid Richer, Ahmed Dahmani, Caroline Guibaudet, Olivier Déas, Stefano Cairo, Ludmilla De Plater, Marine Dubois, Fariba Némati, Christine Sedlik, Jean-Gabriel Judde, Nicolas Girard, Ivan Bieche, Eliane Piaggio, Didier Decaudin. Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1718.
Collapse
Affiliation(s)
- Elodie Montaudon
- 1Institut Curie, Laboratory of Preclinical Investigation (LIP), Paris, France
| | | | - Wilfrid Richer
- 3Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Ahmed Dahmani
- 1Institut Curie, Laboratory of Preclinical Investigation (LIP), Paris, France
| | - Caroline Guibaudet
- 1Institut Curie, Laboratory of Preclinical Investigation (LIP), Paris, France
| | | | | | - Ludmilla De Plater
- 1Institut Curie, Laboratory of Preclinical Investigation (LIP), Paris, France
| | - Marine Dubois
- 3Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Fariba Némati
- 1Institut Curie, Laboratory of Preclinical Investigation (LIP), Paris, France
| | - Christine Sedlik
- 3Institut Curie, PSL Research University, INSERM U932, Paris, France
| | | | - Nicolas Girard
- 5Institut Curie, Department of Medical Oncology, Paris, France
| | - Ivan Bieche
- 2Institut Curie, Genetics Department, Paris, France
| | - Eliane Piaggio
- 3Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Didier Decaudin
- 1Institut Curie, Laboratory of Preclinical Investigation (LIP), Paris, France
| |
Collapse
|
37
|
Leruste A, Caudana P, Tauziede-Espariat A, Han ZY, Ramos RN, Nikolic J, Tosello J, Brohard S, Andrianteranagna M, Chauvin C, Masliah-Planchon J, Sedlick C, Coulomb A, Galmiche-Rolland L, Ranchere D, Benaroch P, Waterfall JJ, Delattre O, Piaggio E, Bourdeaut F. ATRT-35. SMARCB1-DEFICIENT TUMORS ACTIVATE BOTH INNATE AND ADAPTIVE IMMUNE RESPONSES AND ARE SUSCEPTIBLE TO CHECKPOINT BLOCKADE AND TLR3 ACTIVATION. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Amaury Leruste
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U830, Paris, France
| | - Pamela Caudana
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U932, Paris, France
| | | | - Zhi-Yan Han
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U830, Paris, France
| | - Rodrigo N Ramos
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U932, Paris, France
| | - Jovan Nikolic
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U932, Paris, France
| | - Jimena Tosello
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U932, Paris, France
| | - Solene Brohard
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U830, Paris, France
| | | | - Céline Chauvin
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U830, Paris, France
| | | | - Christine Sedlick
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U830, Paris, France
| | - Aurore Coulomb
- Armand Trousseau Hospital, AP-HP, Department of Pathology, Paris, France
| | | | | | - Philippe Benaroch
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U932, Paris, France
| | - Joshua J Waterfall
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U830, Paris, France
| | - Olivier Delattre
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U830, Paris, France
| | - Eliane Piaggio
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U932, Paris, France
| | - Franck Bourdeaut
- Paris-Sciences-Lettres, Institut Curie Research Center, INSERM U830, Paris, France
- Paris-Sciences-Lettres, Institut Curie Hospital, Department of Pediatric Oncology, Adolescents and Young Adults, Paris, France
| |
Collapse
|
38
|
Smaldini PL, Trejo F, Cohen JL, Piaggio E, Docena GH. Systemic IL-2/anti-IL-2Ab complex combined with sublingual immunotherapy suppresses experimental food allergy in mice through induction of mucosal regulatory T cells. Allergy 2018; 73:885-895. [PMID: 29319881 DOI: 10.1111/all.13402] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2017] [Indexed: 12/22/2022]
Abstract
BACKGROUND Therapeutic tolerance restoration has been proven to modify food allergy in patients and animal models and although sublingual immunotherapy (SLIT) has showed promise, combined therapy may be necessary to achieve a strong and long-term tolerance. AIMS In this work, we combined SLIT with systemic administration of IL-2 associated with an anti-IL-2 monoclonal antibody (IL-2/anti-IL-2Ab complex or IL-2C) to reverse the IgE-mediated experimental allergy. MATERIALS AND METHODS Balb/c mice were sensitized with cholera toxin and milk proteins and orally challenged with allergen to elicit hypersensitivity reactions. Then, allergic mice were treated with a sublingual administration of very low amounts of milk proteins combined with intraperitoneal injection of low doses of IL-2C. The animals were next re-exposed to allergens and mucosal as well as systemic immunological parameters were assessed in vivo and in vitro. RESULTS The treatment reduced serum specific IgE, IL-5 secretion by spleen cells and increased IL-10 and TGF-β in the lamina propria of buccal and duodenal mucosa. We found an augmented frequency of IL-10-secreting CD4+ CD25+ Foxp3+ regulatory T cells (Treg) in the submaxilar lymph nodes and buccal lamina propria. Tregs were sorted, characterized and adoptively transferred to naïve mice, which were subsequently sensitized. No allergy was experienced in these mice and we encouragingly discovered a faster and more efficient tolerance induction with the combined therapy compared with SLIT. CONCLUSION The combination of two therapeutic strategies rendered Treg-mediated tolerance more efficient compared to individual treatments and reversed the established IgE-mediated food allergy. This approach highlights the ability of IL-2C to expand Tregs, and it may represent a promising disease-modifying therapy for managing food allergy.
Collapse
Affiliation(s)
- P. L. Smaldini
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP); CONICET y Universidad Nacional de La Plata; La Plata Argentina
| | - F. Trejo
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP); CONICET y Universidad Nacional de La Plata; La Plata Argentina
| | - J. L. Cohen
- Université Paris-Est; UMR_S955; UPEC; Créteil France
- Inserm, U955; Equipe 21; Créteil France
- Hôpital Henri Mondor; UPEC; APHP; Inserm; CIC Biothérapie; Créteil France
| | - E. Piaggio
- Institut Curie; PSL Research University; INSERM U932; Translational Immunotherapy team; Paris France
- Institut Curie; Centre d'Investigation Clinique Biothérapie CICBT 1428; Paris France
| | - G. H. Docena
- Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP); CONICET y Universidad Nacional de La Plata; La Plata Argentina
| |
Collapse
|
39
|
Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. Front Immunol 2018; 9:444. [PMID: 29593717 PMCID: PMC5857565 DOI: 10.3389/fimmu.2018.00444] [Citation(s) in RCA: 115] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2017] [Accepted: 02/19/2018] [Indexed: 12/13/2022] Open
Abstract
Tumor necrosis factor α (TNF) is a potent pro-inflammatory cytokine that has deleterious effect in some autoimmune diseases, which led to the use of anti-TNF drugs in some of these diseases. However, some rare patients treated with these drugs paradoxically develop an aggravation of their disease or new onset autoimmunity, revealing an immunosuppressive facet of TNF. A possible mechanism of this observation is the direct and positive effect of TNF on regulatory T cells (Tregs) through its binding to the TNF receptor type 2 (TNFR2). Indeed, TNF is able to increase expansion, stability, and possibly function of Tregs via TNFR2. In this review, we discuss the role of TNF in graft-versus-host disease as an example of the ambivalence of this cytokine in the pathophysiology of an immunopathology, highlighting the therapeutic potential of triggering TNFR2 to boost Treg expansion. We also describe new targets in immunotherapy of cancer, emphasizing on the putative suppressive effect of TNF in antitumor immunity and of the interest of blocking TNFR2 to regulate the Treg compartment.
Collapse
Affiliation(s)
- Benoît L Salomon
- Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Mathieu Leclerc
- Université Paris-Est and INSERM U955, Créteil, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, Assistance Publique Hôpitaux de Paris (APHP), Hôpital H. Mondor, Créteil, France
| | - Jimena Tosello
- Center of Cancer Immunotherapy and Centre d'Investigation Clinique Biothérapie 1428, Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - Emilie Ronin
- Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Eliane Piaggio
- Center of Cancer Immunotherapy and Centre d'Investigation Clinique Biothérapie 1428, Institut Curie, PSL Research University, INSERM U932, Paris, France
| | - José L Cohen
- Université Paris-Est and INSERM U955, Créteil, France.,Centre d'Investigation Clinique Biothérapie, Assistance Publique Hôpitaux de Paris (APHP), Hôpital H. Mondor, Créteil, France
| |
Collapse
|
40
|
Canale FP, Ramello MC, Núñez N, Araujo Furlan CL, Bossio SN, Gorosito Serrán M, Tosello Boari J, Del Castillo A, Ledesma M, Sedlik C, Piaggio E, Gruppi A, Acosta Rodríguez EA, Montes CL. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8 + T Cells. Cancer Res 2018; 78:115-128. [PMID: 29066514 DOI: 10.1158/0008-5472.can-16-2684] [Citation(s) in RCA: 240] [Impact Index Per Article: 40.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2016] [Revised: 04/10/2017] [Accepted: 10/18/2017] [Indexed: 11/16/2022]
Abstract
The ability of CD8+ T lymphocytes to eliminate tumors is limited by their ability to engender an immunosuppressive microenvironment. Here we describe a subset of tumor-infiltrating CD8+ T cells marked by high expression of the immunosuppressive ATP ecto-nucleotidase CD39. The frequency of CD39highCD8+ T cells increased with tumor growth but was absent in lymphoid organs. Tumor-infiltrating CD8+ T cells with high CD39 expression exhibited features of exhaustion, such as reduced production of TNF and IL2 and expression of coinhibitory receptors. Exhausted CD39+CD8+ T cells from mice hydrolyzed extracellular ATP, confirming that CD39 is enzymatically active. Furthermore, exhausted CD39+CD8+ T cells inhibited IFNγ production by responder CD8+ T cells. In specimens from breast cancer and melanoma patients, CD39+CD8+ T cells were present within tumors and invaded or metastatic lymph nodes, but were barely detectable within noninvaded lymph nodes and absent in peripheral blood. These cells exhibited an exhausted phenotype with impaired production of IFNγ, TNF, IL2, and high expression of coinhibitory receptors. Although T-cell receptor engagement was sufficient to induce CD39 on human CD8+ T cells, exposure to IL6 and IL27 promoted CD39 expression on stimulated CD8+ T cells from human or murine sources. Our findings show how the tumor microenvironment drives the acquisition of CD39 as an immune regulatory molecule on CD8+ T cells, with implications for defining a biomarker of T-cell dysfunction and a target for immunotherapeutic intervention.Significance: The tumor microenvironment elicits a subset of functionally exhausted CD8+ T cells by creating conditions that induce cell surface expression of CD39, an immunosuppressive molecule that can be therapeutically targeted to restore effector T-cell function. Cancer Res; 78(1); 115-28. ©2017 AACR.
Collapse
Affiliation(s)
- Fernando P Canale
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina
| | - María C Ramello
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina
| | - Nicolás Núñez
- SiRIC TransImm, Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, INSERM U932, Institut Curie, Paris, France
| | - Cintia L Araujo Furlan
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina
| | - Sabrina N Bossio
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina
| | - Melisa Gorosito Serrán
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina
| | - Jimena Tosello Boari
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina
| | | | | | - Christine Sedlik
- SiRIC TransImm, Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, INSERM U932, Institut Curie, Paris, France
- Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Eliane Piaggio
- SiRIC TransImm, Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, INSERM U932, Institut Curie, Paris, France
- Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Adriana Gruppi
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina
| | - Eva A Acosta Rodríguez
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina
| | - Carolina L Montes
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Ciudad Universitaria, Córdoba, Argentina.
| |
Collapse
|
41
|
Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I. mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. Oncoimmunology 2017; 6:e1358330. [PMID: 29147616 DOI: 10.1080/2162402x.2017.1358330] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Accepted: 07/18/2017] [Indexed: 12/24/2022] Open
Abstract
Immunotherapy for bladder cancer has given promising results. Here we aimed to evaluate the possible involvement and prognostic value of 33 genes involved in the immune response during bladder carcinogenesis. Expression levels were assessed by quantitative real-time RT-PCR in normal and tumor human bladder samples. Immunohistochemistry was performed to evaluate the protein expression of 2 genes and relation of the mRNA and protein levels was analyzed. Tumors were obtained from 154 patients (83 with muscle-invasive bladder cancer [MIBC] and 71 non-MIBC [NMIBC]) who underwent transurethral bladder resection or radical cystectomy between 2002 and 2006. All patients signed an informed consent. Results of molecular analyses were coupled with survival analyses. Overall, 25 genes (75.8%) were significantly overexpressed in MIBC and 15 (45.5%) were deregulated in NMIBC as compared with normal tissue. On multivariate analysis, risk of NMIBC recurrence was increased with high FOXP3/CD8 ratio and overexpression of OX40L (p = 0.016 and p = 0.0039, respectively). In MIBC, a molecular signature of 3 genes (OX40L, CD8 and TIGIT) was significantly associated with prognosis in terms of recurrence-free and overall survival (p = 0.0007 and p = 0.007). RT-PCR findings were confirmed by immunohistochemistry for CD8 and FOXP3, with high association between mRNA and protein levels. Finally, risk of recurrence of non-muscle-invasive bladder cancer was increased with high FOXP3/CD8 ratio and OX40L overexpression. We identified a 3 gene molecular signature associated with prognosis of muscle-invasive bladder cancer. These results confirm the useful role of immune checkpoints in bladder carcinogenesis and suggest targets for therapy.
Collapse
Affiliation(s)
- Constance Le Goux
- Department of Genetic, Institut curie, Unité de pharmacogénomique, Service de génétique, Paris, France
| | - Sophie Vacher
- Department of Genetic, Institut curie, Unité de pharmacogénomique, Service de génétique, Paris, France
| | - Géraldine Pignot
- Department of Urology, Institut Paoli-Calmettes, Service d'Urologie, Marseille, France
| | - Mathilde Sibony
- Department of Pathology, Université Paris Descartes; Hôpital Cochin, Service d'Anatomopathologie, Paris, France
| | | | - Benoit Terris
- Department of Pathology, Université Paris Descartes; Hôpital Cochin, Service d'Anatomopathologie, Paris, France
| | - Eliane Piaggio
- Department of Translational Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Translational Immunotherapy Siric Team, Centre d'Investigation Clinique Biothérapie CICBT , Paris, France
| | - Marc Zerbib
- Department of Urology, Université Paris Descartes, Hôpital Cochin, Service d'Urologie, Paris, France
| | - Diane Damotte
- Department of Pathology, Université Paris Descartes; Hôpital Cochin, Service d'Anatomopathologie, Paris, France.,Centre de Recherche des Cordeliers, Cancer et Immunité anti tumorale, INSERM U1138, Paris, France
| | - Ivan Bieche
- Department of Genetic, Institut curie, Unité de pharmacogénomique, Service de génétique, Paris, France.,Université Paris Descartes, Paris, France
| |
Collapse
|
42
|
Herbelin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefevre L, Abdallah M, Piccirilli N, Lavoue V, Catros V, Piaggio E, Gombert JM, Barbarin A. Eomesodermin together with KIR/NKG2A membrane receptors and CD49d as an useful strategy to identify NK-like CD8(+) T cells with innate features in humans: focusing on cancer diseases. The Journal of Immunology 2017. [DOI: 10.4049/jimmunol.198.supp.196.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Among the burgeoning family of unconventional T cells, innate-like CD8(+) T cells bear a memory phenotype without having encountered a foreign antigen and can respond to innate-like IL-12+IL-18 stimulation. Although the concept of innate memory (IM) CD8(+) T cells is now well-established in mice, whether an equivalent memory NK-like T-cell population exists in humans remains under debate. We recently reported that CD8(+) T cells responding to innate-like IL-12+IL-18 stimulation and co-expressing the transcription factor Eomesodermin (Eomes) and KIR/NKG2A membrane receptors with a memory/EMRA phenotype may represent a new, functionally distinct innate T cell subset in humans.
Here, we proposed Eomes together with KIR/NKG2A and CD49d as a signature to standardize the identification of this innate CD8(+) T-cell subset in humans. Focusing on cancer diseases, we have provided new insights into the potential role of these IM CD8(+) T cells in a physiopathological context in humans. Based on empirical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome controlled by the immune system, and in solid tumors, we have observed both the possible contribution of IM CD8(+) T cells to cancer disease control and their susceptibility to tumor immune subversion. Finally, we have investigated the involvement of IL-4 and IL-15 in the generation of the IM CD8(+) T cell pool and its dependency on promyelocytic leukemia zinc finger (PLZF)-expressing invariant Natural Killer T (iNKT) cells.
All in all, this study significantly contributes to understanding of the physiopathological role of NK-like CD8(+) T cells in humans and raises the question of the possible involvement of an iNKT/IM CD8(+) T cell axis in cancer.
Collapse
|
43
|
Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefèvre L, Abdallah M, Piccirilli N, Morin B, Lavoue V, Catros V, Piaggio E, Herbelin A, Gombert JM. Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases. Front Immunol 2017; 8:316. [PMID: 28396661 PMCID: PMC5366313 DOI: 10.3389/fimmu.2017.00316] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 03/06/2017] [Indexed: 11/13/2022] Open
Abstract
Unconventional T cells are defined by their capacity to respond to signals other than the well-known complex of peptides and major histocompatibility complex proteins. Among the burgeoning family of unconventional T cells, innate-like CD8(+) T cells in the mouse were discovered in the early 2000s. This subset of CD8(+) T cells bears a memory phenotype without having encountered a foreign antigen and can respond to innate-like IL-12 + IL-18 stimulation. Although the concept of innate memory CD8(+) T cells is now well established in mice, whether an equivalent memory NK-like T-cell population exists in humans remains under debate. We recently reported that CD8(+) T cells responding to innate-like IL-12 + IL-18 stimulation and co-expressing the transcription factor Eomesodermin (Eomes) and KIR/NKG2A membrane receptors with a memory/EMRA phenotype may represent a new, functionally distinct innate T cell subset in humans. In this review, after a summary on the known innate CD8(+) T-cell features in the mouse, we propose Eomes together with KIR/NKG2A and CD49d as a signature to standardize the identification of this innate CD8(+) T-cell subset in humans. Next, we discuss IL-4 and IL-15 involvement in the generation of innate CD8(+) T cells and particularly its possible dependency on the promyelocytic leukemia zinc-finger factor expressing iNKT cells, an innate T cell subset well documented for its susceptibility to tumor immune subversion. After that, focusing on cancer diseases, we provide new insights into the potential role of these innate CD8(+) T cells in a physiopathological context in humans. Based on empirical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome controlled by the immune system, and in solid tumors, we observe both the possible contribution of innate CD8(+) T cells to cancer disease control and their susceptibility to tumor immune subversion. Finally, we note that during tumor progression, innate CD8(+) T lymphocytes could be controlled by immune checkpoints. This study significantly contributes to understanding of the role of NK-like CD8(+) T cells and raises the question of the possible involvement of an iNKT/innate CD8(+) T cell axis in cancer.
Collapse
Affiliation(s)
- Alice Barbarin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France
| | - Emilie Cayssials
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Service d'Hématologie et d'Oncologie Biologique, CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Florence Jacomet
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France; Service d'Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
| | - Nicolas Gonzalo Nunez
- Institut Curie, PSL Research University, INSERM U932, Paris, France; SiRIC Translational Immunotherapy Team, Translational Research Department, Research Center, Institut Curie, PSL Research University, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Sara Basbous
- INSERM 1082, Poitiers, France; Université de Poitiers, Poitiers, France
| | | | - Myriam Abdallah
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France
| | | | | | - Vincent Lavoue
- INSERM U1242, Rennes, France; CHU de Rennes, Rennes, France
| | - Véronique Catros
- CHU de Rennes, Rennes, France; INSERM U991, Rennes, France; CRB Santé de Rennes, Rennes, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris, France; SiRIC Translational Immunotherapy Team, Translational Research Department, Research Center, Institut Curie, PSL Research University, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - André Herbelin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Jean-Marc Gombert
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France; Service d'Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
| |
Collapse
|
44
|
Simon T, Pogu J, Rémy S, Brau F, Pogu S, Maquigneau M, Fonteneau JF, Poirier N, Vanhove B, Blancho G, Piaggio E, Anegon I, Blancou P. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 inducers. J Autoimmun 2017; 81:44-55. [PMID: 28342735 DOI: 10.1016/j.jaut.2017.03.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Revised: 03/09/2017] [Accepted: 03/12/2017] [Indexed: 11/28/2022]
Abstract
Developing protocols aimed at inhibiting effector T cells would be key for the treatment of T cell-dependent autoimmune diseases including type 1 autoimmune diabetes (T1D) and multiple sclerosis (MS). While heme oxygenase-1 (HO-1) inducers are clinically approved drugs for non-immune-related diseases, they do have immunosuppressive properties when administered systemically in rodents. Here we show that HO-1 inducers inhibit antigen-specific effector T cells when injected intradermally together with the T cell cognate antigens in mice. This phenomenon was observed in both a CD8+ T cell-mediated model of T1D and in a CD4+ T cell-dependent MS model. Intradermal injection of HO-1 inducers induced the recruitment of HO-1+ monocyte-derived dendritic cell (MoDCs) exclusively to the lymph nodes (LN) draining the site of intradermal injection. After encountering HO-1+MoDCs, effector T-cells exhibited a lower velocity and a reduced ability to migrate towards chemokine gradients resulting in impaired accumulation to the inflamed organ. Intradermal co-injection of a clinically approved HO-1 inducer and a specific antigen to non-human primates also induced HO-1+ MoDCs to accumulate in dermal draining LN and to suppress delayed-type hypersensitivity. Therefore, in both mice and non-human primates, HO-1 inducers delivered locally inhibited effector T-cells in an antigen-specific manner, paving the way for repositioning these drugs for the treatment of immune-mediated diseases.
Collapse
Affiliation(s)
- Thomas Simon
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France; INRA USC1383, IECM; LUNAM Université, Oniris, Nantes, EA4644, France; Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Julien Pogu
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France
| | - Séverine Rémy
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France
| | - Frédéric Brau
- Université Côte d'Azur, Inserm, CNRS, IPMC, 06560, Valbonne, France
| | - Sylvie Pogu
- INRA USC1383, IECM; LUNAM Université, Oniris, Nantes, EA4644, France
| | - Maud Maquigneau
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France
| | | | - Nicolas Poirier
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France; OSE Immunotherapeutics, 44200 Nantes, France
| | - Bernard Vanhove
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France
| | - Gilles Blancho
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France
| | | | - Ignacio Anegon
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France
| | - Philippe Blancou
- Université de Nantes, Inserm, UMR1064, Center for Research in Transplantation and Immunology, 44093, Nantes, France; Université Côte d'Azur, Inserm, CNRS, IPMC, 06560, Valbonne, France; INRA USC1383, IECM; LUNAM Université, Oniris, Nantes, EA4644, France.
| |
Collapse
|
45
|
Pérol L, Lindner JM, Caudana P, Nunez NG, Baeyens A, Valle A, Sedlik C, Loirat D, Boyer O, Créange A, Cohen JL, Rogner UC, Yamanouchi J, Marchant M, Leber XC, Scharenberg M, Gagnerault MC, Mallone R, Battaglia M, Santamaria P, Hartemann A, Traggiai E, Piaggio E. Loss of immune tolerance to IL-2 in type 1 diabetes. Nat Commun 2016; 7:13027. [PMID: 27708334 PMCID: PMC5059699 DOI: 10.1038/ncomms13027] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 08/25/2016] [Indexed: 12/28/2022] Open
Abstract
Type 1 diabetes (T1D) is characterized by a chronic, progressive autoimmune attack against pancreas-specific antigens, effecting the destruction of insulin-producing β-cells. Here we show interleukin-2 (IL-2) is a non-pancreatic autoimmune target in T1D. Anti-IL-2 autoantibodies, as well as T cells specific for a single orthologous epitope of IL-2, are present in the peripheral blood of non-obese diabetic (NOD) mice and patients with T1D. In NOD mice, the generation of anti-IL-2 autoantibodies is genetically determined and their titre increases with age and disease onset. In T1D patients, circulating IgG memory B cells specific for IL-2 or insulin are present at similar frequencies. Anti-IL-2 autoantibodies cloned from T1D patients demonstrate clonality, a high degree of somatic hypermutation and nanomolar affinities, indicating a germinal centre origin and underscoring the synergy between cognate autoreactive T and B cells leading to defective immune tolerance. Type 1 diabetes is driven by T-cell autoimmunity to pancreatic islet cells. Here the authors show that autoreactive anti-IL-2 T and B cells are present in type 1 diabetes patients, and that anti-IL-2 antibodies precede diabetes onset in mice, suggesting their potential as a diagnostic marker.
Collapse
Affiliation(s)
- Louis Pérol
- Sorbonne Universités, Pierre and Marie Curie University Paris 06, Paris 75005, France.,Centre National de la Recherche Scientifique, UMR 7211, Paris 75013, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U 959, Immunology- Immunopathology-Immunotherapy (I3), Paris 75013, France.,Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - John M Lindner
- Novartis Institutes for Biomedical Research, Basel 4056, Switzerland
| | - Pamela Caudana
- Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Nicolas Gonzalo Nunez
- Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Audrey Baeyens
- Sorbonne Universités, Pierre and Marie Curie University Paris 06, Paris 75005, France.,Centre National de la Recherche Scientifique, UMR 7211, Paris 75013, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U 959, Immunology- Immunopathology-Immunotherapy (I3), Paris 75013, France
| | - Andrea Valle
- Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Christine Sedlik
- Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Delphine Loirat
- SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Olivier Boyer
- INSERM, U905, Rouen 76183, France.,Normandie Univ. IRIB, Rouen 76183, France.,Rouen University Hospital, Laboratory of Immunology, Rouen 76183, France
| | - Alain Créange
- Service de Neurologie, Groupe Hospitalier Henri Mondor, AP-HP, Créteil F-94010, France.,EA 4391, Université Paris Est, Créteil F-94010, France
| | - José Laurent Cohen
- Université Paris-Est Créteil, Créteil F-94010, France.,INSERM U 955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil F-94010, France.,AP-HP, Groupe Hospitalier Henri-Mondor Albert-Chenevier, CIC-BT-504, Créteil F-94010, France
| | - Ute Christine Rogner
- Institut Pasteur, CNRS URA 2578, Département Biologie du développement et cellules souches, Paris 75015, France
| | - Jun Yamanouchi
- Julia McFarlane Diabetes Research Centre and Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine. University of Calgary, Calgary, Alberta, Canada T2N 4N1
| | - Martine Marchant
- Novartis Institutes for Biomedical Research, Basel 4056, Switzerland
| | | | - Meike Scharenberg
- Novartis Institutes for Biomedical Research, Basel 4056, Switzerland
| | - Marie-Claude Gagnerault
- INSERM, U1016, Cochin Institute, DeAR Lab, Paris 75014, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Diabétologie, Paris 75014, France.,Paris Descartes University, Sorbonne Paris Cité, Faculté de Médecine, Paris 75270, France
| | - Roberto Mallone
- INSERM, U1016, Cochin Institute, DeAR Lab, Paris 75014, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Diabétologie, Paris 75014, France.,Paris Descartes University, Sorbonne Paris Cité, Faculté de Médecine, Paris 75270, France
| | - Manuela Battaglia
- Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Pere Santamaria
- Julia McFarlane Diabetes Research Centre and Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine. University of Calgary, Calgary, Alberta, Canada T2N 4N1.,Institut D'Investigacions Biomediques August Pi i Sunyer, Barcelona 08036, Spain
| | - Agnès Hartemann
- Department of Medicine Faculty, Université Pierre et Marie Curie-Paris 6, Paris 75005, France.,Department of Endocrinology, Nutrition and Diabetes, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière-Charles Foix Hospital, Paris 75013, France
| | | | - Eliane Piaggio
- Sorbonne Universités, Pierre and Marie Curie University Paris 06, Paris 75005, France.,Centre National de la Recherche Scientifique, UMR 7211, Paris 75013, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U 959, Immunology- Immunopathology-Immunotherapy (I3), Paris 75013, France.,Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| |
Collapse
|
46
|
Knittel D, Gadzinski A, Hua S, Denizeau J, Savatier A, de la Rochère P, Boulain JC, Amigorena S, Piaggio E, Sedlik C, Léonetti M. Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response. Vaccine 2016; 34:3093-3101. [PMID: 27154391 DOI: 10.1016/j.vaccine.2016.04.073] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 03/31/2016] [Accepted: 04/25/2016] [Indexed: 10/21/2022]
Abstract
Heparan sulfates (HS) are carbohydrate moieties of HS proteoglycans (HSPGs). They often represent alternative attachment points for proteins or microorganisms targeting receptors. HSPGs, which are ubiquitously expressed, thereby participate in numerous biological processes. We previously showed that MHC class II-restricted antigen presentation is increased when antigens are coupled to HS ligands, suggesting that HSPGs might contribute to adaptive immune responses. Here, we examined if HSPG targeting influences other aspects of immune responses. We found that coupling of an HS ligand to the antigen increases antigen presentation to CD4(+) and CD8(+) T-cells after antigen targeting to membrane immunoglobulins or to MHC-II molecules. Moreover, this increased stimulating capacity correlates with an enhanced CD8(+) immune response in mice. Last, animals control more effectively the growth of Ova-expressing tumour cells when they are immunized with an Ova construct targeting HSPGs and MHC-II molecules. Our results indicate that ubiquitous molecules can influence both MHC class I- and MHC class II-restricted antigen presentation and behave as co-receptors during T-cell stimulation. Moreover, they suggest that tumour-antigens endowed with the ability to target both HSPGs and MHC-II molecules could be of value to increase CD8(+) immune response and control tumour-growth, opening new perspectives for the design of highly immunogenic protein-based vaccines.
Collapse
Affiliation(s)
- Delphine Knittel
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France
| | - Adeline Gadzinski
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France
| | - Stéphane Hua
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France
| | - Jordan Denizeau
- Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France
| | - Alexandra Savatier
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France
| | - Philippe de la Rochère
- Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France
| | - Jean-Claude Boulain
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France
| | - Sebastian Amigorena
- Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France
| | - Eliane Piaggio
- Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France
| | - Christine Sedlik
- Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France
| | - Michel Léonetti
- Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France.
| |
Collapse
|
47
|
Sedlik C, Heitzmann A, Viel S, Ait Sarkouh R, Batisse C, Schmidt F, De La Rochere P, Amzallag N, Osinaga E, Oppezzo P, Pritsch O, Sastre-Garau X, Hubert P, Amigorena S, Piaggio E. Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen. Oncoimmunology 2016; 5:e1171434. [PMID: 27622021 DOI: 10.1080/2162402x.2016.1171434] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Revised: 02/12/2016] [Accepted: 03/23/2016] [Indexed: 01/17/2023] Open
Abstract
Antibody-drug conjugates (ADC), combining the specificity of tumor recognition by monoclonal antibodies (mAb) and the powerful cytotoxicity of anticancer drugs, are currently under growing interest and development. Here, we studied the potential of Chi-Tn, a mAb directed to a glyco-peptidic tumor-associated antigen, to be used as an ADC for cancer treatment. First, we demonstrated that Chi-Tn specifically targeted tumor cells in vivo. Also, using flow cytometry and deconvolution microscopy, we showed that the Chi-Tn mAb is rapidly internalized - condition necessary to ensure the delivery of conjugated cytotoxic drugs in an active form, and targeted to early and recycling endosomes. When conjugated to saporin (SAP) or to auristatin F, the Chi-Tn ADC exhibited effective cytotoxicity to Tn-positive tumor cells in vitro, which correlated with the level of tumoral Tn expression. Furthermore, the Chi-Tn mAb conjugated to auristatin F also exhibited efficient antitumor activity in vivo, validating for the first time the use of an anti-Tn antibody as an effective ADC.
Collapse
Affiliation(s)
- Christine Sedlik
- Institut Curie, PSL Research University, Paris, France; INSERM U932, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Adèle Heitzmann
- Institut Curie, PSL Research University, Paris, France; INSERM U932, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Sophie Viel
- Institut Curie, PSL Research University, Paris, France; INSERM U932, Paris, France
| | - Rafik Ait Sarkouh
- Institut Curie, PSL Research University, Paris, France; CNRS UMR3666/INSERM U 1143, Paris, France
| | - Cornélie Batisse
- Institut Curie, PSL Research University, Paris, France; CNRS UMR3666/INSERM U 1143, Paris, France
| | - Frédéric Schmidt
- Institut Curie, PSL Research University, Paris, France; CNRS UMR3666/INSERM U 1143, Paris, France
| | | | - Nathalie Amzallag
- Institut Curie, PSL Research University, Paris, France; INSERM U932, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Eduardo Osinaga
- Departamento de Inmunobiología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay; Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - Pablo Oppezzo
- Departamento de Inmunobiología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay; Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - Otto Pritsch
- Departamento de Inmunobiología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay; Institut Pasteur de Montevideo, Montevideo, Uruguay
| | | | - Pascale Hubert
- Institut Curie, PSL Research University, Paris, France; INSERM U932, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Sebastian Amigorena
- Institut Curie, PSL Research University, Paris, France; INSERM U932, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, Paris, France; INSERM U932, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| |
Collapse
|
48
|
Goldstein JD, Burlion A, Zaragoza B, Sendeyo K, Polansky JK, Huehn J, Piaggio E, Salomon BL, Marodon G. Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression. PLoS One 2016; 11:e0153682. [PMID: 27077371 PMCID: PMC4831811 DOI: 10.1371/journal.pone.0153682] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 03/30/2016] [Indexed: 12/03/2022] Open
Abstract
The IL-2/JAK3/STAT-5 signaling pathway is involved on the initiation and maintenance of the transcription factor Foxp3 in regulatory T cells (Treg) and has been associated with demethylation of the intronic Conserved Non Coding Sequence-2 (CNS2). However, the role of the JAK/STAT pathway in controlling Foxp3 in the short term has been poorly investigated. Using two different JAK/STAT pharmacological inhibitors, we observed a detectable loss of Foxp3 after 10 min. of treatment that affected 70% of the cells after one hour. Using cycloheximide, a general inhibitor of mRNA translation, we determined that Foxp3, but not CD25, has a high turnover in IL-2 stimulated Treg. This reduction was correlated with a rapid reduction of Foxp3 mRNA. This loss of Foxp3 was associated with a loss in STAT-5 binding to the CNS2, which however remains demethylated. Consequently, Foxp3 expression returns to normal level upon restoration of basal JAK/STAT signaling in vivo. Reduced expression of several genes defining Treg identity was also observed upon treatment. Thus, our results demonstrate that Foxp3 has a rapid turn over in Treg partly controlled at the transcriptional level by the JAK/STAT pathway.
Collapse
Affiliation(s)
- Jérémie D. Goldstein
- Sorbonne Universités, UPMC Univ Paris 06, UMR-S CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI), INSERM U1135, CNRS ERL 8255, Paris, France
| | - Aude Burlion
- Sorbonne Universités, UPMC Univ Paris 06, UMR-S CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI), INSERM U1135, CNRS ERL 8255, Paris, France
| | - Bruno Zaragoza
- Sorbonne Universités, UPMC Univ Paris 06, UMR-S CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI), INSERM U1135, CNRS ERL 8255, Paris, France
| | - Kélhia Sendeyo
- Sorbonne Universités, UPMC Univ Paris 06, UMR-S CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI), INSERM U1135, CNRS ERL 8255, Paris, France
| | - Julia K. Polansky
- Department of Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | - Jochen Huehn
- Department of Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | | | - Benoit L. Salomon
- Sorbonne Universités, UPMC Univ Paris 06, UMR-S CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI), INSERM U1135, CNRS ERL 8255, Paris, France
| | - Gilles Marodon
- Sorbonne Universités, UPMC Univ Paris 06, UMR-S CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI), INSERM U1135, CNRS ERL 8255, Paris, France
- * E-mail:
| |
Collapse
|
49
|
Abstract
Interleukin-2 (IL-2) is an old molecule with brand new functions. Indeed, IL-2 has been first described as a T-cell growth factor but recent data pointed out that its main function in vivo is the maintenance of immune tolerance. Mechanistically, IL-2 is essential for the development and function of CD4(+) Foxp3(+) regulatory T cells (Treg cells) that are essential players in the control of immune responded to self, tumors, microbes and grafts. Treg cells are exquisitely sensitive to IL-2 due to their constitutive expression of the high affinity IL-2 receptor (IL-2R) and the new paradigm suggests that low-doses of IL-2 could selectively boost Treg cells in vivo. Consequently, a growing body of clinical research is aiming at using IL-2 at low doses as a tolerogenic drug to boost endogenous Treg cells in patients suffering from autoimmune or inflammatory conditions. In this manuscript, we briefly review IL-2/IL-2R biology and the role of IL-2 in the development, maintenance, and function of Treg cells; and also its effects on other immune cell populations such as CD4(+) T helper cells and CD8(+) memory T cells. Then, focusing on type 1 diabetes, we review the preclinical studies and clinical trials supporting the use of low-doses IL-2 as a tolerogenic immunotherapy. Finally, we discuss the limitations and future directions for IL-2 based immunotherapy.
Collapse
Affiliation(s)
- Louis Pérol
- INSERM U932, 26 rue d'Ulm, 75005, Paris, France.
- Institut Curie, Section Recherche, 26 rue d'Ulm, 75005, Paris, France.
| | - Eliane Piaggio
- INSERM U932, 26 rue d'Ulm, 75005, Paris, France
- Institut Curie, Section Recherche, 26 rue d'Ulm, 75005, Paris, France
| |
Collapse
|
50
|
Elhage R, Cheraï M, Levacher B, Darrasse-Jeze G, Baillou C, Zhao X, Khatib AM, Piaggio E, Klatzmann D. C-Terminal Cleavage of Human Foxp3 at a Proprotein Convertase Motif Abrogates its Suppressive Function. Scand J Immunol 2015; 81:229-39. [DOI: 10.1111/sji.12275] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Accepted: 01/19/2015] [Indexed: 12/14/2022]
Affiliation(s)
- R. Elhage
- Immunology-Immunopathology-Immunotherapy (I3); Sorbonne Universités; UPMC Univ Paris 06; UMR 7211; UMRS 959; Paris France
- Immunology-Immunopathology-Immunotherapy (I3); CNRS; UMR 7211 and FRE 3632; Paris France
- Immunology-Immunopathology-Immunotherapy (I3); INSERM; UMRS 959; Paris France
| | - M. Cheraï
- Biotherapy Department; AP-HP; Hôpital Pitié-Salpêtrière; Paris France
- Clinical Investigation Center in Biotherapy (CIC-BTi); AP-HP; Hôpital Pitié-Salpêtrière; Paris France
| | - B. Levacher
- Immunology-Immunopathology-Immunotherapy (I3); Sorbonne Universités; UPMC Univ Paris 06; UMR 7211; UMRS 959; Paris France
- Immunology-Immunopathology-Immunotherapy (I3); CNRS; UMR 7211 and FRE 3632; Paris France
- Immunology-Immunopathology-Immunotherapy (I3); INSERM; UMRS 959; Paris France
| | - G. Darrasse-Jeze
- Immunology-Infectiology and Hematology Department (I2H); Sorbonne Paris Cité; Université Paris Descartes Paris 05; Institut Necker Enfants Malades (INEM); UMRS 1151; Paris France
- Immunology-Infectiology and Hematology Department; INSERM; UMRS 1151; Paris France
| | - C. Baillou
- Immunology and Infectious Diseases Center (CIMI); Sorbonne Universités; UPMC Univ Paris 06; UMRS CR7; UMRS 1135; Paris France
- Immunology and Infectious Diseases Center (CIMI); INSERM; UMRS 1135; Paris France
| | - X. Zhao
- Immunology-Immunopathology-Immunotherapy (I3); Sorbonne Universités; UPMC Univ Paris 06; UMR 7211; UMRS 959; Paris France
- Immunology-Immunopathology-Immunotherapy (I3); CNRS; UMR 7211 and FRE 3632; Paris France
- Immunology-Immunopathology-Immunotherapy (I3); INSERM; UMRS 959; Paris France
| | - A.-M. Khatib
- Angiogenesis and Cancer Microenvironment Laboratory (LAMC); Université Bordeaux 1; Talence France
- Angiogenesis and Cancer Microenvironment Laboratory (LAMC); INSERM; UMRS 1029; Talence France
| | - E. Piaggio
- Institut Curie; Section Recherche; INSERM UMRS 932; Immunity and Cancer; Paris France
- INSERM Center of Clinical Investigation (CBT507 IGR-Curie); Paris France
| | - D. Klatzmann
- Immunology-Immunopathology-Immunotherapy (I3); Sorbonne Universités; UPMC Univ Paris 06; UMR 7211; UMRS 959; Paris France
- Immunology-Immunopathology-Immunotherapy (I3); CNRS; UMR 7211 and FRE 3632; Paris France
- Biotherapy Department; AP-HP; Hôpital Pitié-Salpêtrière; Paris France
- Clinical Investigation Center in Biotherapy (CIC-BTi); AP-HP; Hôpital Pitié-Salpêtrière; Paris France
- Inflammation-Immunopathology-Biotherapy Department (i2B); AP-HP; Hôpital Pitié-Salpêtrière; Paris France. Immunology-Immunopathology-Immunotherapy (I3); INSERM; UMRS 959; Paris France
| |
Collapse
|